Podcasts about american society

We often think of negotiation as a series of rigid maneuvers performed in glass-walled boardrooms. We imagine sharp suits, legal jargon, and the clinical pursuit of "more." But what happens when you take the negotiation out of the boardroom and into the boiler room?   In this interview, your host, Cindy Watson, is joined by Larry Weingarten, who views the world through a uniquely practical yet profound lens. Larry is the author of The Philosopher's Wrench; he got his general contractor's license in 1982, and Larry has been a member of the National Association of Corrosion Engineers (NACE) and the American Society of Heating, Refrigeration, and Air-Conditioning Engineers (ASHRAE).   Buckle up, as Cindy and Larry will be discussing about Creativity, Heart, And Irreverence In Everyday Negotiations.   In this episode, you will learn:   Listening as the foundation of good communication and negotiation. What is deep listening look like in real life? How to approach conflict creatively? How do scarcity show up in everyday interactions, and how can we shift out of that kind of approach? The misconception that people have about negotiation . Simple practice to handle difficult conversation. And many more!   Learn more about Larry:   Website: https://www.larryweingarten.com/   Checkout Larry's book:  The Philosopher's Wrench: Using Your Creativity, Heart & Tools to Fix the World If you're looking to up-level your negotiation skills, I have everything from online to group to my signature one-on-one mastermind & VIP experiences available to help you better leverage your innate power to get more of what you want and deserve in life. Check out our website at www.artofFeminineNegotiation.com if that sounds interesting to you. Get Cindy's book here:   Amazon   https://www.amazon.com/Art-Feminine-Negotiation-Boardroom-Bedroom-ebook/dp/B0B8KPCYZP?inf_contact_key=94d07c699eea186d2adfbddfef6fb9e2&inf_contact_key=013613337189d4d12be8d2bca3c26821680f8914173f9191b1c0223e68310bb1   EBook   https://www.amazon.com/Art-Feminine-Negotiation-Boardroom-Bedroom-ebook/dp/B0B8KPCYZP?inf_contact_key=94d07c699eea186d2adfbddfef6fb9e2&inf_contact_key=013613337189d4d12be8d2bca3c26821680f8914173f9191b1c0223e68310bb1   Barnes and Noble   https://www.barnesandnoble.com/w/the-art-of-feminine-negotiation-cindy-watson/1141499614?ean=9781631959776 CONNECT WITH CINDY: Website: www.womenonpurpose.ca Facebook:  https://www.facebook.com/womenonpurposecommunity/ Instagram: https://www.instagram.com/womenonpurposecoaching/ LinkedIn: linkedin.com/in/thecindywatson Show: https://www.womenonpurpose.ca/media/podcast-2/ (X) Twitter:  https://twitter.com/womenonpurpose1 YouTube:https://www.youtube.com/@hersuasion Email:cindy@womenonpurpose.ca  

In this episode of the Neuroveda Podcast for Complex Health, Gillian Ehrlich, ARNP, sits down with Dr. Carley Squires to discuss apheresis, with a focus on therapeutic plasma exchange (TPE), also known as plasmapheresis.Apheresis means the removal of something from the blood, and the type of apheresis depends on what is being removed. At Neuroveda, the focus is plasma apheresis, meaning plasma is removed and replaced with albumin and saline. Therapeutic plasma exchange is an extracorporeal blood purification technique designed to remove a portion of plasma that may contain potentially harmful substances such as autoantibodies, inflammatory cytokines, immune complexes, and other immune mediators involved in immune dysregulation.Dr. Squires explains the broader umbrella of therapeutic apheresis, including red blood cell exchange, leukapheresis, plateletpheresis, lipid/LDL apheresis, extracorporeal photopheresis, and H.E.L.P. apheresis. While H.E.L.P. apheresis is not currently available in the United States, interest in apheresis expanded during the rise of long COVID, when patients began traveling internationally for treatment.Therapeutic plasma exchange has been used for decades in hospital settings, primarily for autoimmune disease, but is now being explored for additional applications including long COVID, neuroinflammatory conditions, and longevity medicine. Research suggests TPE may help support immune modulation through mechanisms such as:• Removal of immune complexes• Reduction of inflammatory cytokines• Correction of altered Th1/Th2 immune balance• Increased T regulatory and T suppressor cellsEmerging research has also explored TPE for PANDAS/PANS, pediatric autoimmune neuropsychiatric disorders triggered by infection.Referenceshttps://www.sciencedirect.com/science/article/pii/S0149763417305833https://pubmed.ncbi.nlm.nih.gov/10513708/While additional research is still needed for many of these applications, Neuroveda has also observed significant clinical improvements over the past several years, including reductions in toxic burden from mycotoxins, heavy metals, solvents, plastics, and other persistent environmental toxins.The episode also reviews current American Society for Apheresis (ASFA) guidance, which places many emerging uses of apheresis into Category III, meaning the optimal role is still being defined and treatment decisions should be individualized.ReferenceConnelly-Smith L, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice. J Clin Apher. 2023.Listeners will also hear what to expect from a TPE treatment at Neuroveda. Each session lasts approximately 2–4 hours, during which blood circulates through a machine that separates and removes plasma while returning the remaining blood components with replacement fluid.Although the procedure may sound invasive, TPE is generally well tolerated and safely performed in outpatient settings. Vital signs are monitored throughout treatment, and most patients experience only mild side effects such as fatigue, lightheadedness, or temporary electrolyte shifts.One unique aspect of Neuroveda's approach is the integration of Ayurvedic medicine with modern therapeutic plasma exchange. Ayurvedic therapies use oils, massage, steam, and other treatments to mobilize lipophilic toxins from deeper tissues back into circulation. Because TPE removes substances circulating in the bloodstream, these therapies may help prepare the body for detoxification.This aligns with Panchakarma, Ayurveda's classical detoxification process, which includes rakta moksha, traditionally translated as “blood liberation.” In a modern context, TPE can be viewed as a technological evolution of this ancient concept.Rather than functioning as a stand-alone cure, TPE is often most effective as part of a comprehensive program that may include functional medicine, regenerative medicine,

For people living with kidney disease, clinical trials can offer hope—but not without questions or concerns. Today, we talk with Dr. Nadine Barrett, Glenda Roberts, and Luz Baqueiro about lived experience, community trust, and the power of being asked. In this episode we heard from:  Dr. Nadine J. Barrett is a Professor in the Department of Social Sciences and Health Policy in the Division of Public Health Sciences and the inaugural Senior Associate Dean of Community Engagement and Equity in Research at Wake Forest School of Medicine, she is Associate Director of Community Outreach and Engagement for Wake Forest Comprehensive Cancer Center, the Clinical Translational Science Institute and the Maya Angelou Center for Health Equity. Prior to joining Wake Forest, Dr. Barrett served 13 years in senior leadership roles at Duke University, as the Founding Director of both the Duke Center for Equity in Research and the nationally awarded, Duke Cancer Institute's Office of Health Equity. She is also President of the national Association of Cancer Care Centers, in Washington DC. A medical sociologist by training, Dr. Barrett is a health disparities researcher, expert equity strategist, and a nationally recognized leader in facilitating authentic community, healthcare, and academic partnerships to advance health equity. She develops multi-level interventions to address implicit bias, structural and systemic racism, and inequities that limit access to quality research and trustworthy health care among underserved and marginalized populations. Dr. Barrett brings an equity lens to her work and collaborations to enhance healthcare systems, close the disparities gap in health outcomes, and increase diverse and broad representation in research participation and the research workforce. Glenda Roberts: Prior to joining the Mount Sinai Center for Kidney Disease Innovation as the Director of Communications and Patient Engagement, Glenda V. Roberts was an Information Technology executive with over 35 years of experience with top-caliber corporations, including General Electric, Microsoft and Johnson & Johnson. She was also the Executive Director of the Seattle Transplant House, and the Director of External Relations & Patient Engagement at the University of Washington Center for Dialysis Innovation (CDI) and the Kidney Research Institute (KRI). Before going on dialysis, Glenda managed the progression of her disease for over 40 years using diet and exercise. Since her transplant in 2010, she's completed nine half marathons. Based upon her personal experience with kidney disease, Glenda is a passionate activist for kidney research and patients living with kidney disease. She's involved in myriad patient-centered national and international health care transformation initiatives.  All are focused on addressing patient preferences and improving patient-reported outcomes.   Glenda brings the patient voice to several NIH/NIDDK government and industry research efforts (Kidney Precision Medicine Project, APOLLO), as well as the American Society of Nephrology's Current & Emerging Threats (C-ET) Steering Committee. She's the inaugural co-chair of the Critical Path Institute's Biomarker Data Repository Governance Committee, and a member of the Kidney Health Initiative (KHI) Board of Directors. Additionally, she contributes to the Advisory Boards of LifeCenter Northwest and Home Dialyzors United, and over 15 other industry and academic research advisory committees/boards focused on transplantation, kidney, cardiovascular, and metabolic health. As an ambassador for the National Kidney Foundation, the American Kidney Fund, and the American Association of Kidney Patients, Glenda's advocacy tirelessly advances the voices, needs, and aspirations of the kidney community worldwide. Luz Baqueiro serves as a patient advocate with the National Kidney Foundation (NKF), providing feedback and helping develop new initiatives to better support the Latin American community affected by chronic kidney disease. She also raises awareness of the barriers faced by patients living with renal failure while educating and supporting her community in Georgia. In 2019, Luz was diagnosed with end-stage renal disease (ESRD). With limited resources  in Georgia, she relied on emergency in-hospital dialysis for a year. In August 2021, through self-determination, self-education, and the support of her family and community, she received a kidney transplant.   Additional Resources Clinical Trial Information Hub What is a Clinical Trial? Are Clinical Trials Safe?   Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.

In this episode, Maddy Roche sits down with Zeena Regis, MDiv,  Director of Priority Populations at Compassion and Choices, to explore one of the most requested, and most avoided, conversations in the Childfree community: medical aid in dying.Zeena brings nearly 20 years of end-of-life experience, beginning as a hospice chaplain and evolving into a national advocate for equitable access to end-of-life options. She and Maddy unpack what medical aid in dying actually is, who it's for, and why having open conversations about death leads to better care for everyone, whether or not medical aid in dying is ever something you'd personally choose.In This Episode, You'll Learn:Why medical aid in dying is one option within a broader spectrum of end-of-life care, and what the legal safeguards around it actually look likeHow Childfree adults face unique risks when no healthcare proxy or estate documents are in place.How community, storytelling, and even art can open the door to death planning conversations that feel impossible to start aloneWhy having a healthcare proxy who truly knows you and is prepared to advocate for your wishes makes a difference in the quality of your final chapterJoin a Live Q&A with Zeena Regis: Title: Designing Your End-of-Life: A Live Q&A with Zeena Regis, MDivDate: 4/1/2026   Time: 5 PM EasternRegistration Link: https://us02web.zoom.us/webinar/register/WN_g-AYE_5GR1O2nRM-7l9tCg Episode Host:Maddy Roche: Chief Growth Officer at Childfree Trust® and responsible for all sales and marketing initiatives.Episode Guest:Zeena Regis, MDiv serves as the Director of Faith Engagement and Priority Populations at Compassion & Choices, improving care, expanding options, and empowering everyone to chart their end-of-life journey. Prior to her role with Compassion & Choices, Zeena served as a chaplain and grief care specialist for over a decade. Zeena also serves on the faculty of Columbia Theological Seminary's Older Adult Ministry Certification program and was selected as a 2024 American Society on Aging Fellow. Zeena is also a playwright, and her latest work, A Free Black Woman's Guide to Death & Dying, was selected for the Synchronicity Theatre's arts incubator project.Learn more about Compassion and Choices: https://compassionandchoices.org/ About Childfree InsightsChildfree Insights is a trusted resource for life planning without children. It explores financial planning, estate planning, relationships, and long-term decisions for adults building a future without kids. Home of Childfree Wealth® and Childfree Trust®.Connect with Us: Ready to work on building better financial habits? Connect with our financial planning team at childfreewealth.com or learn more about estate planning at childfreetrust.com. Follow Childfree Life by Design on your favorite podcast platform and join the conversation on social media: Instagram: https://www.instagram.com/childfreeinsightsFacebook: https://www.facebook.com/ChildfreeInsights/LinkedIn: https://www.linkedin.com/company/childfreeinsightsYouTube: https://www.youtube.com/@ChildfreeInsights Disclaimer: This podcast is for educational & entertainment purposes. Please consult your advisor before implementing any ideas heard on this podcast.

In this episode of the DermSurgery Digest, you'll hear a summary of the surgical oncology and reconstruction articles in the March 2026 issue of Dermatologic Surgery followed by commentary from special guest contributors Ramona Behshad, MD, and Alexander Valiga, MD. This podcast is hosted by Dermatologic Surgery Digital Content Editor, Naomi Lawrence, MD, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery. In this podcast series the cosmetic and general dermatology articles in the March issue of Dermatologic Surgery are featured in a separate episode. Your feedback is encouraged. Please contact communicationstaff@asds.net. 

In this episode of the DermSurgery Digest, you'll hear a summary of the cosmetic and general dermatology articles in the March 2026 issue of Dermatologic Surgery followed by commentary from special guest contributors Kira Minkis, MD, PhD, and Pooja Rambhia, MD. This podcast is hosted by Dermatologic Surgery Digital Content Editor, Naomi Lawrence, MD, and co-hosted by Michael Renzi, MD. Dermatologic Surgery is the official publication of the American Society for Dermatologic Surgery. In this podcast series the surgical oncology and reconstruction articles in the March issue of Dermatologic Surgery are featured in a separate episode. Your feedback is encouraged. Please contact communicationstaff@asds.net.

DML's morning insight on a hot topic trending in the United States.

Kenneth Batcheldor was a British clinical psychologist who, during the final two decades of his life, investigated the paranormal through direct experiments in table-turning. The final fruit of that work was an essay, compiled from Batcheldor's notebooks by Patric Giesler, entitled “Notes on the Elusiveness Problem in Relation to a Radical View of Paranormality.” Published in the Journal of the American Society for Psychical Research in 1994, it remained unknown to JF and Phil until Shannon Taggart called their attention to it quite recently. Since the theory Batcheldor presents here with admirable lucidity is deeply attuned to ideas they have been discussing on Weird Studies for nearly a decade, they decided to devote an episode to it. The core idea is by far the weirdest of all—in a sense, it is the weird itself. Read Batcheldor's essay on the Weird Studies Patreon. Visit Weirdosphere to enroll in Phil's upcoming 5-week course, "A Musical Tarot." Pierre-Yves Martel's Weird Studies: Volume 3 will be available for preorder on March 13. Visit his Bandcamp page for details. REFERENCES K. M. Wehrstein, “Kenneth Batcheldor” in Psi Encyclopedia   Kenneth Batcheldor, “Notes on the Elusiveness Problem in Relation to a Radical View of Paranormality,” ed. Patric Giesler, The Journal of the American Society for Psychical Research 88, no. 2 (1994): 90-116.  Kenneth Batcheldor, “Contributions to the Theory of PK Induction from Sitter-Group Work,” Journal of the American Society for Psychical Research 78 (1984): 105-122.  George P. Hansen, The Trickster and the Paranormal  Quintin Meillassoux, After Finitude  Joshua Ramey, “Contingency Without Reason: Speculation after Meillassoux”  Kenneth Batcheldor, Videos of Table Tipping  Weird Studies, Episode 24 with Lionel Snell  David Lynch, Wild at Heart  William James, The Principles of Psychology Tom Cheetham, Imaginal Love  A. Irving Hallowell, Ojibwa Ontology, Behavior, and World View  Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of the Financial Guys Podcast, Mike Hoeflich and Glenn Wiggle tackle a wide range of political issues shaping the national conversation. They begin with frustration over the SAVE Act and the debate around voter ID laws, arguing that adding unrelated policy issues makes meaningful election reform harder to pass. The conversation expands into broader concerns about election integrity, the idea of making Election Day a national holiday, and the challenges of immigration, assimilation, and cultural integration in the United States. Later, Mike and Glenn discuss rising political tensions at home and abroad, including terrorism concerns, unrest in major cities, and America's ongoing conflicts in the Middle East. They wrap up with a sharp critique of Washington's political class, comparing the relentless drive of elite athletes to what they see as complacency among many elected officials—and why accountability and stronger leadership in government are needed now more than ever. (00:01:58) Legislation Focus: Voter ID Requirements in SAVE Act(00:05:42) First Saturday National Voting Day Proposal(00:15:45) Controversy Over Muslims in American Society(00:17:44) Melting Pot Analogy in Integration Process(00:30:03) Athletes vs Legislators: Commitment to Excellence(00:30:59) Politicians' Dedication to Positive Change(00:33:06) Straightforward GOP Senator's Admirable Stance(00:36:31) Barriers to Unseating Incumbents in Politics

Are you looking to level up your presentation and connection skills as an admin professional? In this mini episode, take some quick tips from expert trainer and speaker Dr. Mary Ritz. Recorded at APC 2025 and produced by the American Society of Administrative Professionals - ASAP. Learn more and submit a listener question at asaporg.com/podcast.

if you have any feedback, please send us a text! Thank you!Welcome to another episode of Vital Times.In January 2026 the American Society of Anesthesiologists (ASA) and the Society for Pediatric Anesthesia (SPA) issued an updated joint communication regarding severe neurologic complications, including stroke and death, in healthy young adult (oldest reported so far is 36) and pediatric patients of Venezuelan ancestry following routine general anesthesia. There have been about 36 known or suspected cases worldwide although that number seems to be regularly increasing. The majority of cases have occurred in South American countries, with six reported in in the United States and eight in Europe. Genetic testing on a subset of the patients found a genetic mutation in mitochondrial DNA, known as the ND4 mutation. (for an interview with the physician and mother listen here https://www.instagram.com/reel/DUb4tYGjfdM/?utm_source=ig_web_copy_link .In July 2025, anecdotal communications from South American anesthesiology societies described cases of patients having severe complications from general anesthesia. Despite incomplete and emerging clinical and scientific information, ASA and SPA felt the severity of the cases warrant an expert opinion communication to inform anesthesiologists and their patients.Detailed family histories of patients who were recently affected revealed that all were of Venezuelan heritage and several had family members who also had adverse outcomes after an otherwise uneventful anesthetic. Four anesthesiologists at the leading edge of this newly discovered condition joined the show today to explain how it was discovered, what is known and what we can do about it. Dr. Jim Fehr is the past President of the Society for Pediatric Anesthesia, and the Division chief of Pediatric Anesthesia at Stanford Lucile Packard Children's Hospital. He is one of the coauthors of the joint statement, a member of the Society for PEdiatri Anesthesia's Wake Up Safe initiative and very involved with Patient Safety. Dr. Veronica Zoghbi is a Venezuelan pediatric anesthesiologist and Director of Pediatric Regional Anesthesia at the University of Miami in Miami, Florida.  South Florida and Miami have one of the highest concentrations of people from Venezuela in the USA. She and our other 2 guests are members of VAPOR (Venezuelan Anesthesiologist Perioperative Risk Reduction) Dr. Claudia Bruguera Torres is a pediatric anesthesiologist from Venezuela and Assistant Professor at Cincinnati Children's Hospital. Dr. Luis Rodriguez is a Venezuelan Pediatric Anesthesiologist from Miami FL, and currently serves as the Vice President for the Florida Society of AnesthesiologistsFinally, if complications occur in patients with the ND4 mutation, anesthesiologists should report the case to their institutions' patient safety organization and the Anesthesia Incident Reporting System of the Anesthesia Quality Institute.

Transitions from the hospital to nursing homes or other post-acute care settings are critical moments for patient safety—especially when antibiotics are involved. In this episode of the SHEA Podcast, host Dr. Lauren Gleason discusses the real-world challenges of managing antibiotics during these transitions with experts Dr. Susan Huang, Dr. Swati Gaur, and Chad Worz, PharmD. The conversation explores common barriers such as medication availability, timing of doses, pharmacy logistics, cost considerations, and monitoring needs. Our speakers share practical insights on how clearer communication and better coordination between hospitals, nursing homes, and pharmacies can reduce errors, prevent missed doses, and support safer, more effective antibiotic care. This episode was developed in collaboration with the Post-Acute and Long-Term Care Medical Association (PALTmed) and the American Society of Consultant Pharmacists (ASCP). Resources: - "You Can Help! Improving Antibiotic Stewardship & Infection Prevention in Nursing Homes": https://learningce.shea-online.org/content/you-can-help-improving-antibiotic-stewardship-infection-prevention-nursing-homes#group-tabs-node-course-default1

If you're on Wegovy, Zepbound, Ozempic, or Mounjaro — and worried about what happens when you stop — this episode is for you. The fear of gaining it all back is real. But weight regain is not inevitable. It's manageable. And I'm going to show you how. "What happens when you stop your GLP-1?" This is one of the most common questions I get in my clinic every single week. It's time I answered it publicly — with science, not fear. In this episode, I break down exactly what happens in your body when you stop your GLP-1, why weight regain happens, and the five pillars you need to protect your results, whether you're stopping by choice or out of necessity. Listen now! Episode Highlights: The physiological reason hunger surges and metabolism slows when you stop GLP-1s  What the SURMOUNT-4 clinical trial tells us about weight regain after stopping Tirzepatide Who is at highest risk for regaining weight  The 5 pillars of weight maintenance: protein, resistance training, carb awareness, appetite retraining, and medication transition strategy Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''. Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Send a textThis episode was recorded live at the BakingTECH 2026 meeting in Chicago with our guest, Heather Simpson.Heather Simpson has built a diverse career in the food industry, leveraging her Food Science education from Purdue University. Her journey began at Mars Corp's DoveBar plant gaining experience in production. She then transitioned to the dairy industry, working with a hydrocolloid ingredient company to support McDonald's shake and soft serve products, deepening her expertise in food ingredients and applications.Heather's career path then led her to a sales position with Kraft Food Ingredients, where she honed her skills in client relations and business development. After a hiatus to focus on raising her sons, she re-entered the industry in a sensory role at McDonald's Corporate. Her subsequent work at Jimmy Dean / Tyson Foods involved carrier breads, adding experience in food product innovation. A brief stint at Newlyweds Foods saw her developing English muffins, before joining Tate and Lyle.Heather is currently a Technical Service Account Manager at Tate and Lyle, focused on snack foods and alcoholic beverages. Her varied background and extensive industry knowledge have made her a valuable asset in her role, on what she affectionately calls the "party team," reflecting her enthusiasm and passion for her work.American Society of Baking Website: https://asbe.org/BakingTech Website: https://asbe.org/bakingtech/Got a questions for us? Email us at wolfingdownfoodscience@gmail.comPlease take a minute to help others find our podcast by leaving a rating and comment on your podcasting app!

Hi, It's Michele! Send me a text with who you want as a guest!This episode was recorded at the KBIS Podcast Studio sponsored by AJ Madison and Neal Pann and Apple for Architecture.Laurinda H. Spear, FAIA, PLA, LEED AP, IIDAPrincipal of Arquitectonica As a founding principal of Arquitectonica and ArquitectonicaGEO, Ms. Spear has been active from the beginning, and has participated in the design of many projects undertaken by both firms. She studied fine arts at Brown University, received her Master of Architecture degree from Columbia University and later a Master of Landscape Architecture from Florida International University. She has taught at Harvard and the University of Miami. Ms. Spear is interested in educating others in design excellence, she has lectured around the world, and her work has been exhibited in many prestigious museums.Laurinda has designed many of the firm's signature projects, and her designs have won over a hundred design awards.  Many of Ms. Spear's projects have been featured in books, as well as prominent magazines and professional journals. She was also instrumental in the expansion of Arquitectonica into design fields beyond architecture and planning.  She first established the interior design practice, Arquitectonica Interiors, which earned the firm its place in the Interior Design Hall of Fame.  She also created the design products group, Laurinda Spear Products, which has over 150 products on the market under dozens of global brands. In 2005, Laurinda established the landscape architecture practice ArquitectonicaGEO, focusing on environmental land planning, sustainability, innovation, and landscape design.Laurinda is a Fellow of the American Institute of Architects, a Registered Landscape Architect, a member of the American Society of Landscape Architects, and a LEED Accredited Professional.  She is a recipient of the AIA Silver Medal, the Rome Prize in Architecture and the ULI Lifetime Achievement Award.  Cecilia E. Ramos of LutronCecilia leads Architecture & Design at Lutron where she drives strategy, creative direction, and design engagement globally. She holds degrees in architecture from MIT and Princeton and has traveled the world as a lighting designer for luxury brands including Louis Vuitton, Christian Dior, and Dior Parfums. A frequent international speaker and co-author of the book Architectural Lighting: Designing with Light and Space (Princeton Architectural Press, 2011) she finds creative energy though hiking the world's stunning landscapes, painting, and designing jewelry for her own brand. Link to MGHarchitect: MIchele Grace Hottel, Architect website for scheduling a consultation for an architecture and design project and guest and podcast sponsorship opportunities:https://www.mgharchitect.com/

In this episode of The Geoholics, we go full geospatial nerd mode with several leaders from the American Society for Photogrammetry and Remote Sensing (ASPRS) — a professional organization that's been shaping the mapping and imaging sciences since 1934. That's right… these folks were advancing mapping science before lidar was cool and long before anyone thought strapping cameras to drones was a good idea. Joining the show are Dr. Balaji Ramachandran, Dr. Unal Okyay, Bill Swope, and Scott Dunham, representing the ASPRS Gulf South Region, where they're working to grow a tight-knit geospatial community across Texas and Louisiana. From certifications to conferences to career-changing connections, this episode dives into why professional organizations still matter in an industry evolving at warp speed. We kick things off at 30,000 feet discussing what ASPRS actually does and why surveyors, drone pilots, photogrammetrists, lidar specialists, and GIS pros should care. With nearly a century of history behind it, ASPRS has helped establish standards, promote education, and advance technologies that form the backbone of modern geospatial workflows. The conversation also digs into ASPRS certifications — including Certified Photogrammetrist (CP) and Certified Mapping Scientist (CMS) — and how these credentials can elevate careers, validate expertise, and help professionals stand out in a rapidly growing field.  We also preview the ASPRS Gulf South Geospatial Conference, happening at Nicholls State University in Thibodaux, Louisiana, where attendees can expect technical sessions on topics like mobile lidar for railroads, geospatial accuracy standards, photorealistic 3D visualization, and lidar data assessment — plus a panel discussion moderated by your very own Geoholics host....Mr. Kent Groh! Beyond the tech talk, the episode highlights initiatives like the Jim Gillis Memorial Education Fund, which helps remove financial barriers for students and young professionals pursuing careers in mapping sciences — proving that investing in the next generation is just as important as pushing the technology forward. Organizations like ASPRS play a critical role in maintaining standards, professional credibility, and ethical practice as geospatial technology becomes more accessible to everyone. If you care about the future of geospatial technology, professional credibility, and building a stronger community in the mapping sciences, this is an episode you won't want to miss. Music by Pink Floyd!

Mechanical engineering honors senior Dalton Robinson sat down with the #GINNing gang to discuss his Auburn journey, the amazing Montgomery Advanced Manufacturing Laboratories and Auburn's chances at once again sticking it to Princeton and the rest of the also-rans at the American Society of Naval Engineers' annual Promoting Electric Propulsion Competition.  

Logan McKnight is the founder of GoodKnight Consulting and a strategic advisor to MedTech executives navigating growth, leadership challenges, and operational complexity. Logan shares her nearly 20-year journey from pre-med to neuromonitoring technologist to CEO, and explains why she now focuses on helping leaders build teams that scale without sacrificing culture or burning out. She discusses lessons learned managing remote surgical service teams, why “simple scales,” and how mission, vision, and values enable better decisions and hiring beyond gut instinct.  Guest links: https://www.goodknightconsulting.net/ Charity supported: ASPCA Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host & Editor: Lindsey Dinneen Producer: Velentium Medical   EPISODE TRANSCRIPT Episode 075 - Logan McKnight [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello, and welcome back to another episode of The Leading Difference podcast. I'm your host, Lindsey, and today I am delighted to welcome Logan McKnight. Logan is the founder of GoodKnight Consulting and a strategic advisor to MedTech executives navigating growth, leadership challenges and operational complexity. With nearly 20 years in neuromonitoring and surgical services, including experience as a CEO, VP of Operations and business development leader, Logan brings an experienced perspective to executive leadership. She works with directors, VPs, and C-suite leaders to build teams that can scale without sacrificing culture or burning out. Well, welcome to the show, Logan. I'm so glad to speak with you today, and thank you so much for being here. [00:01:34] Logan McKnight: Yeah, it's great to be here. I appreciate you inviting me. [00:01:36] Lindsey Dinneen: Of course. I'd love if you wouldn't mind starting off by sharing just a little bit about yourself, your background, and what led you to MedTech. [00:01:45] Logan McKnight: Of course. Yeah. So my name is Logan McKnight and I have been in medtech for almost the last 20 years. And I think my journey, I, a lot of people have a very similar like origin story of haphazardly finding their way into medtech. I was pre-med in college. I wanted to go into veterinary school and I think I panicked honestly last minute, not really wanting to go. I interned under vet who basically dissuaded me from doing all the work of vet school and said go to med school. And feeling a little lost, I found my way to medtech, particularly neural monitoring, which was a field, pretty niche, but basically I got trained by a company to go in and run equipment and monitor patient's nervous systems during surgery. And to me, just having my bachelor's degree and having that level of impact and being able to jump right into patient care without having to go to more, you know, years and years of schooling was right up my alley and it's been such a wild ride. You know, I was a technologist and then I became a manager and then VP of development of business development, and head of contracting. And then I went over to a small company where I was the vice president of the whole company, and then eventually CEO, and now I'm consulting for medtech companies. So it's been a really fun journey that I didn't plan at all. [00:03:06] Lindsey Dinneen: Yeah. Okay. Well, excellent. And that brings up so many questions, but to start, so you were thinking originally you might wanna be a vet. Do you have you know, like, did you grow up with animals? Did you just have an amazing love for them? Where did that come from? [00:03:23] Logan McKnight: You know, honestly, I think I would've had way more animals, but my parents were a lot more reasonable than I was. So we just had the regular pets, but I grew up like horseback riding and in the Midwest, in Ohio. So I was around a lot of farm animals and things like that and I was part of like FFA and horticulture. So future Farmers of America. And I actually was really interested in large animals because I didn't wanna deal with people, I didn't wanna deal with people or their pets. So, and you know, and so that was what panicked me about med school was like the whole plan was veterinary school was to avoid the people part. And then I found through medtech you know, neuromonitoring and surgery where my patients are asleep. And so I still got to do all the things that I love, like providing impact, but then, you know, not having to worry about, I guess all for me I just had my head like all the challenges and complications that deal dealing with patients that I thought would make my job and life really difficult. So it's been really fun to kind of focus on just like the care and how to move things forward and explore this big, wide open space of how to impact people's lives in surgery. [00:04:31] Lindsey Dinneen: Yeah. And you know what's interesting about that too is, though, I think it sounds like throughout your, though, as you've, you know, gone from technologist and then you've had all of these amazing career changes and growth basically. It sounds like, you know, you have developed though your own kind of leadership style, so even though maybe originally you weren't sure about dealing with people, so to speak, you've actually excelled at it. So I'm curious how that has evolved for you in creating and managing teams. [00:05:03] Logan McKnight: Yeah. You know, it's interesting. I think like initially I was trying to control all these variables before I got into leadership in people, and then realized like you can't do that once you get to actually working with people. And once you almost like acknowledge and recognize, you can't control that but there's some beauty in that of you just allow for what you allow and then you know, you have to give people the ability to function like at their level. And you create the parameters. But other than that, like some magic happens when you don't try to control every single thing. And I see so many, especially new managers, you know, being like, "I need to control everything." And they're wondering why they're exhausted or their team's not respecting them. And it's like, gotta let go, gotta let go of the wheel a little bit. So, you know, I think those are some lessons and sometimes they just come with time and experience. [00:05:55] Lindsey Dinneen: Yeah, absolutely. Yeah. So, when you started, well, let's go back to the beg, maybe it's kind of at the beginning of your career. What are some things that you learned as a technologist and as you were growing within the hospital systems themselves, that contributed to basically where you would become now to become an entrepreneur and all of that. [00:06:21] Logan McKnight: Yeah, I mean, I will be very honest, and this is not meant to be a dig at anybody who I'd worked with or any boss. But I just, I went to work for a private company and we went and we were almost like hired mercenaries. So we would go to like, you know, every day I was in a different hospital. I didn't know my schedule till the night before. I rarely saw my manager and, you know, rarely saw other members of my team and it really felt like I was very isolated and alone. And it added to my burnout and also feeling like I didn't have anyone watch, like looking out for me and my back as a younger employee. And I realized there was so much room for improvement there in how you manage a team remotely. And so I think I, I just like mentally I was a psychology major before I switched to pre-med, and so I think like the, like human brain, because I was, you know, neuroscience, but like psychology, I think is so fascinating to me and the way people tick and what makes them tick. And I, I'm a big believer if you can figure out the way people tick, you can unlock so many things in the world and like you can, you know, you can be the most brilliant person, but if you can't communicate effectively, if you can't manage a team, you're really not gonna take things to the next level because you're not gonna activate those people around you to perform and get something done. So I feel like it was a case study for me to kind of watch like these managers and struggle and I'm like, "Ah, that's what I'm not going to do." [00:07:47] Lindsey Dinneen: Yes. Yeah. Sometimes learning from examples that maybe you wish you didn't have to learn from though can be the best teachers and actually serve your, you know, your own leadership style and your people that you end up getting to influence. It actually does help in the long term, but so. [00:08:06] Logan McKnight: Totally. [00:08:07] Lindsey Dinneen: So when you started GoodKnight Consulting, what was the impetus for that? I mean, you'd had this you've had this amazing career so far. You're ready kind of just for the next step or what sparked that? [00:08:19] Logan McKnight: You know, it's interesting, I stepped down from my CEO position 'cause I was feeling, I was running a neuromonitoring service company in the Pacific Northwest. We also had a professional services arm with neurologists. And then I had a medical billing company that I was running and we did mostly out of network billing. And then we also started a company in India right before COVID. So by 2023, I was fried, I was very burnt out in the way that I felt like I was busy all the time, but not really having the same impact I used to have. I think a lot of that was like I, I got more involved on the litigious side of running a company and then also the medical billing side really takes it out of you. So the thing I enjoyed was the coaching and the mentoring, and once I took a little bit of a step back and thought about what would I do every day for free? You know, like, what would I just love to do? And the reality was coaching other leaders, especially one like scratched my itch for helping people and provide and like, impact, which I realize is my biggest driver is like, how do I impact the most people and walk away with, you know, my life feeling like I've touched people in a positive way, and I think that's, you know, my, my driving force. So that's kind of why I started. And I started honestly just trying to go to leaders individually and offer some webinars and some one-on-one coaching. And then I really realized working with companies actually is the best way to go about this because you get ownership and leadership that's totally aligned and they want that support for their leaders. And then, it's so much easier to see the impact spread throughout an organization, so that's been really cool, is to be this outside force driving an owner or an executive's vision of what they want their company or the team to be. [00:10:07] Lindsey Dinneen: Yeah, and I noticed when I was reading a little bit more about the company, one of the things that I thought was really interesting is you talk about there, this is not just let's say leadership or mindset coaching or something like that, although that is very important as well. It is also about the business strategy. And you talk a lot about, you know, you've been in the position to understand how much, of course, revenue matters. You ha you have to, you know, make sure that's a strong, you know, foundation for the business. So, so how do you balance the two when you work with clients? [00:10:45] Logan McKnight: Yeah, no, that's a great question. I think every client is unique. I have found that just stripping away-- actually with something I, a blog post I was working on today and something I posted on LinkedIn, and it's something I find myself saying to founders and owner operators all the time-- simple scales. And I think, you know, what ends up happening is a lot of times you get this great idea for a product, a service, a company, and you just go. And you don't sometimes sit down and create like the true mission or the vision and like the values of the company. And it's really hard for owner operators and people who are in startup land and you know, small businesses to pause and do that, especially if they've been going for a few years 'cause you know, it's like, "Well, I've been operating without this stuff. It's totally fine." The reality is it's so much easier to grow and scale and also to gut check yourself when you're making decisions and being like "This is the right call because this aligns with our mission and our vision for the company or our growth initiatives for this year. And then it aligns with my values. I feel good about this decision and I can communicate it to people I hire. So I trust those people." And like that's what scales is, the trust and people having like the unified mission and vision and values and like, I know it sounds a little touchy feely, but the reality is like that's actually what I feel like I end up centering owners and operators on. It's less about the minutia and the details and more about like, does this make sense with where you wanna go and the way you, and the way you wanna get there. [00:12:21] Lindsey Dinneen: Yeah. Yeah, exactly. Okay. Yeah, I really like that. And with the emphasis on the unified team in terms of, you know, we don't all have to view life exactly the same, but we need to be aligned, at least with our mission and values and things like that. What do you find are some of the best practices when it comes to building out a team? And on the flip side, what are some things that maybe are common or that feel like they would be good practices, but in reality might not be. Like, what are some lessons learned, I suppose, on both sides? [00:12:56] Logan McKnight: Yeah. I mean, I think, I'll be honest, I think a lot of owners and maybe leaders who've been in their position for a while, like, like there-- I was talking to somebody else about this, about your gut feeling and like, go with your gut and trust me. I was a big go with my gut leader especially as a CEO, but like that doesn't scale because you have to be able to verbalize like, what are the things you're looking for? Why did you pick this person? And so at the end of the day you know, I had a policy when I was probably right, became, when I became a CEO that I needed to like approve after a couple not so great hires, I needed to approve every hire. And like the reality is that's not realistic, that's not gonna scale as you grow. And so I just needed to create the, this is what we're looking for like, you know, we're hiring for attitude. We can train the aptitude, we can train the technical depending on what the job is. But, you know, here's what we're really looking for, is a good fit for the company and the culture. And then, because once I had people who I knew really got that and saw the vision, I knew they were gonna make the right choices. And so I didn't feel like I had to. Be the one making that decision, I could scale it and help, you know, allow my team to hire for the people in the places that they needed and saw. [00:14:09] Lindsey Dinneen: Yeah. Okay. Yeah, I really like that. So, one thing that I thought was interesting, especially so on your LinkedIn profiles, I was, you know, enjoying reading more about you and some of the things you've done. But you had mentioned that sometimes there's a trade off between hitting targets and then you're burning out your team for the opposite. You're protecting your team, but then you're not hitting your targets. Could you speak a little bit more about that and how you help companies sort of overcome that challenge. [00:14:40] Logan McKnight: No, and I mean, I think it's like, I equate like, I think when I first became a leader, you know, talking about how my viewed my other leaders maybe know what not to do, I definitely swung the pendulum too far the other direction when I first started. And I was way too, I don't know, I was way too, all the things I didn't get. And so two, like checking in with my team, "How are you doing?" Not wanting to delegate work to them and doing these things because you know, and so I realized there's you, I think that's like an initial thing a lot of leaders go through is that shift. It's when you get stuck in the one extreme or the other and you don't really find your good at equilibrium, that it's really hard to sustain. And I think it's really important to find your equilibrium of, like, "This drives us to hit quota. This drives us to get our metrics and to for success. And then it does it in a sustainable way that our team's gonna stay." Because to me, like, sustainable. I kind of was thinking about my values even this morning and I'm like, I think fun is really one of my values like, I want to really enjoy like not just my personal life, but my professional life, and I think your job, your company, all of those things is a lot more fun when it's sustainable, right, when you're like exhausted. So finding a way for it to be sustainable for your team, for, you know, and everyone likes to win. Like it's fun to hit quota. It's fun to like crush your metrics and celebrate. So it, how do you know, make that sustainable and fun? And I think that's like a long-term success or recipe for success with a company. [00:16:15] Lindsey Dinneen: Yeah. Yeah. Well, and you know, it's so interesting 'cause actually this has come up a couple of times recently on the podcast is the sort of core value of fun and how much that does actually transform people's experience with the company. And you know, because inevitably you're gonna have those days that are just really tough and hard. And so being able to though have a culture of fun and joy is, it does make a difference. Yeah. [00:16:42] Logan McKnight: No, for sure. I remember when I first started working in surgery and someone asked me, they're like, "Oh, is it like Grey's Anatomy?" And, you know, and I'm like, "It's not nearly as like sexy. Like there's no, you know, doctors in closets and whatever." The, I, it's actually more like the show Scrubs and the reality is, and people are like, "Oh, that seems like goofy and comedy." I'm like, "I know." But the, I think the reality is we view in like healthcare and medtech of like this, you know, taking care of patients, a serious job. We're talking to surgeons. But for anybody who's really good at their job, like, you know, you see, especially in surgery in these high stakes environments, like it's actually the best rooms to be in are a lot of fun because you rely on your team, you know everyone's gonna do well, or you know their job well. If shit hits the fan, the tone changes and you can trust that. But I think because you trust your team. It's fun, you know, in more moments than not because there's just so much trust that when things get serious, people will speak up and it's safe. I think you like when you're psychologically safe, it's enjoyable, it's fun, and you also feel like you can speak up when you say something wrong. And I feel like those are the healthiest like work dynamics, both in healthcare then, especially in medtech when you're putting a product out there, like you want somebody to say something if they see a problem with your product before it goes to market, right? [00:18:05] Lindsey Dinneen: Well, and I love that. I love that perspective too of, you're absolutely right, healthcare, medical devices, it is it is serious by nature and it should be like, we should take our jobs seriously. But at the same times, if we could not maybe take ourselves as seriously and, you know, and infuse the fun and it does help also I think dissipate some of that-- well, some of the really hard, you know, again, those days that are tough it helps to be able to say, you know, take a step back and go, you know what, "It's yes, and." [00:18:37] Logan McKnight: Right. A hundred percent. Yeah. It adds a little like, like brevity to those se really serious moments to be able to feel. You know, and I think that at the end of the day, like you being in whatever place whatever your place is in healthcare, in medtech, like whatever role you're playing, like you are helping advance the field, you're helping patient care. And I think always keeping that in mind, even on like the tough days, like you're advancing something in a good way keeps you centered on like your why and drives you forward in a really good way versus like, you know, and I'll be honest, like I, it got hard for me in my CEO role, like, I think I lost my why a little bit and my driver, because it's very hard to see, "Okay, well how am I impacting patient care positively. How am I impacting the world positively?" when you're chasing down insurance reimbursements and whatnot. And, you know, dealing with hospital shutdowns during COVID. So I think at the end of the day, I realize like I need to find a way for this to be enjoyable and fun because I also realize like I'm my best self and I'm more creative and I'm more in like a problem solving zone when I'm in that, that good mindset. And so I, I look at it as a huge positive to, to figure out what, what drives you and make you happy. [00:19:51] Lindsey Dinneen: Yeah. What drives you makes you happy. And I agree with you, if you can also take a step back sometimes and have that broader perspective and mix it with just a little bit of humor, even if just all you're doing is taking a quick break and watching, I don't know, a funny cat video or something. Yeah. [00:20:10] Logan McKnight: Sure. [00:20:11] Lindsey Dinneen: Reset moments make a difference. So difference, you're a board member of several organizations and I wondered if you could speak a little bit to those organizations and what led you to get involved with them. [00:20:24] Logan McKnight: Yeah. So the two I'm on the board of is one Nepal's Spine Foundation which I went to Nepal with a few surgeons I worked with. And then when I was in figuring out my why when I stepped away the surgeons who are started the foundation invited me to join the board. And actually I will be going to Nepal with them in April and we'll be doing another mission and then hiking to Everspace camp together. I'm looking forward to that, and it's been amazing 'cause I think that's also, I've gotten to go on a lot of mission trips in my career. I've gotten to go to Ghana and Barbados, Dominican Republic, Nepal, India. And so, like I also realized like impact being my driver, like I have so much impact to teach people about neuromonitoring, which isn't a well-known, you know, aspect of surgery always. And so the fact that I could leave a hospital, a community better for going there really was a driver. So the fact that I continued to do that work is really important. And then the second is STRIPES, which is how I met you, women in medtech. And you know, the nice thing is I was looking, I was a, I went back before I fully launched GoodKnight Consulting and became like a device rep just to kind of figure out, you know, do I wanna go back into sales? What do I really wanna do? And I was a little lost and I found my way, you know, I wanted community. And when I found this group, it was just transformative for me. Like I, my mentor was Lisa Jacobs, who is phenomenal and has been inspiring for a very long time. And she actually really pushed me to do my dream and start and really put all into my coaching and consulting. So I'm really grateful for that. And then she invited me to be on the board. So like to continue to give back to an organization that I feel like personally gave me, like it, it's why I am where I am today. It gave me that push I needed in that support. And there's tons of women in the organization like Claire Davis, Kat Hurd, like Courtney Turich. I just, they're all out there, they're all public on LinkedIn. And that was something that honestly, initially scared me. And so just, I was inspired by them, supported, and I think that's a really, you know, great thing when you are becoming an entrepreneur is finding your community and that support. [00:22:42] Lindsey Dinneen: Yeah. Yeah. Well, okay. So I just, I love the fact that you're doing both of those things. The mission work is really cool. It's amazing to hear how you've gotten to use-- well, because you're so driven by impact how you've gotten to do that and then make a big difference in, in the lives of people that, yeah, may otherwise never have had that opportunity or, you know, at least not for a while or whatever. So. [00:23:09] Logan McKnight: Right. [00:23:10] Lindsey Dinneen: Yeah, that, that's really incredible. So, you know, through that or throughout your career, are there any moments that really stand out to you as kind of affirming, "Wow, I am in the right industry at the right time." [00:23:23] Logan McKnight: You know, I think medtech, like always, even if it's not me and something I'm doing, like seeing people who I know in the industry and accomplishments they've made, and organizations that I've either been a part of or supported in some way in my career, like just seeing like the new tech coming out and the advancements they're making, just reaffirms like I'm part of a bigger picture in an ecosystem that's really great. And even, you know, like I, I came from the spine space when I was doing medical device and it spine is, you know, tough. Like ortho's tough, spines tough. That's a lot of competition. But you know, I think. Competition drives quality, and so it's really cool even if you see your competitor doing something, you know, you're like, "Oh man, I wish we would've," but it's getting done. It's, you know, it's pushing the envelope, it's making it better. And I think that's huge. And, you know, really exciting too when I found you and Project Medtech to see how you guys are helping support like startups and investors and people who are looking to get into this space. Because I think that's the other thing is getting fresh perspective and new innovative companies helps everybody like drive, drives the mission forward, drives the impact forward on patient care. [00:24:38] Lindsey Dinneen: Yeah. Yeah. I love that. Yeah. And okay, so another very random thing that I found on your LinkedIn, but I just really liked it 'cause I resonate with this aspect. So you started to paint, you learned how to paint. Tell us about that and does that play a role in your creativity overall, do you think? [00:25:01] Logan McKnight: You know, I think so. So I hosted like a happy hour for girlfriends and we did this thing where we painted like a thrift shop thrift store paintings and like Halloween things in them. And so, and I live in the Pacific Northwest, which is beautiful. We have a hundred year old cabin on three acres, and it's, it was October. It was just like, stunning. And I was looking out in our, my backyard and I was like, "I wanna paint this." And I just sat down. I mean, I'm not artistic. I've never and it looked like a 8-year-old painted it and my partner Joe was like, "Maybe watch a video." It's great. I love it. But, you know, and so I found, you know, like Bob, apparently all, every episode of Bob Ross was on Netflix at least last year. And so I just started watching some videos and some videos on YouTube, and I started getting better and better pretty quickly. Like I, you know, I started, you know, little tutorials here and there. And then I realized, like I was also reading books to help me kind of get in this entrepreneurial mindset like growth mindset or "Mindset" by Carol Dweck, which talks about growth mindset. And I realized like, you can teach yourself to do anything. Like I had told myself for the longest time, I mean, I started my I'm 40 and so I told myself for 40 years, like, "I'm not artistic." That was my box I painted around myself. And then all of a sudden I was like, "Well, let's give it a shot." And so, you know, there's, I realize like you set these boundaries in your parameters in your head and you blow them up a little bit. Like, you know what? Like, let's just see, let's try you know, and I see this with our teenagers too, it's sometimes like when they struggle in school, they'll be like, "I'm not smart, or I'm not this." And I'm like, "You just have to try." Like anything worth doing takes effort. And if everybody quit because they weren't good. The first time or even like the 10th time, like imagine how little progress we would make as a society. So I think if something you wanna do something recognizing, like you can learn to do it. And I think that also helped ignite, like me knowing I could be, do my consulting company and really launch it. And so I just started reaching out to people who had done it and I hired coaches and I started to learn more about what would make it work and what I would need to do. And you know what a novel idea, right? You find the person who's doing what you wanna do and you learn from them. You know, and it's just like that entire journey over the last year was really helpful to, I think, get me to the head place like I needed to be, to like leave the safety of a W2 job and launch a company. Just to like lie, you know, to myself every, and be like, "You can do it." Because, you know, if you start every day with the, "I don't know if this is gonna work," like I, there's no way I would've done this. I really had to tell myself I could do it, it was gonna work, and I realized now that I've gotten past that, it's very harder like to put a boundary around me now. Like now it's a challenge, right? Like if you tell me I can't do something, I'm like, "Oh, let's see." I bet you, you know, even if I'll fail, like the first few times, I want to try to see if I can do it because I now have this delusion that I can teach myself to do just about anything, so. [00:28:18] Lindsey Dinneen: That's awesome. [00:28:20] Logan McKnight: Or not. [00:28:20] Lindsey Dinneen: Yeah, no, that is incredible. And you're absolutely right. I think we can all relate to, at least in some element of our lives, painting boxes around ourselves and going, "I'm not this," or "I'm not that," or "I'll never get to be able to do this. I'll never be proficient." And those things aren't true. It's just what we tell ourselves. So I love the fact that painting opened up those doors for you. [00:28:43] Logan McKnight: Yeah. No it's so true. And I think it's like a. You know, a metaphor for life. And I think I hear that a lot of times from people will be like, "I wish I could do what you," and I'm like, " You can literally do anything." That's how crazy. And, you know, we're in peak New Year's resolution time, right? And I think a lot of people are like, "Oh, I wanna do this and do that." And that's like, you can, you just like, if you wanna be a person that exercises more. Just go start exercising. That's how wild the world, like our brains can make us do whatever we want. So anyway, I'm also a big psychology buff 'cause I, I'm a big believer in like the power of the human brain and what it can do over your decision making and your life and the impact it can have, you know, everything really. [00:29:27] Lindsey Dinneen: Yeah. No, absolutely. Yeah, I couldn't agree more. I love that perspective and yeah, growth mindset is a wonderful gift because, you know, you can explore, you can try, and as long as you're sticking with it and doing those things, then you're not failing. You're just, you're just exploring and then you can just keep exploring and find things that are right for you. And you know, not everything will stick, and that's okay too, so. [00:29:55] Logan McKnight: Yeah, a hundred percent. Yeah. I always tell people "I'm still figuring what I, or figuring out what I wanna do when I grow up." You know, and I think that's an ongoing thing, and I hope when I'm 80, I still am figuring out like what's next. [00:30:06] Lindsey Dinneen: Yeah. [00:30:07] Logan McKnight: It's exciting. So. [00:30:08] Lindsey Dinneen: Yeah. All right, well pivoting the conversation a little bit just for fun. Imagine that you were to be offered a million dollars to teach a masterclass on anything you want. It could be within your industry, but it doesn't have to be. What would you choose to teach? [00:30:24] Logan McKnight: You know, I think this, it ends up being the thing I talk about most. And it's the thing I think I wanted to do initially, but it was really a struggle to just target and talk to managers, especially like frontline managers. But I think that transition from being an independent contributor to becoming a first time leader-- like if I could teach a masterclass in that, I think that would be really fun. I see so many very empathetic and like capable independent contributors, whether they be like rockstar sales rep or even a great like technologist or engineer. And then they were like, "Okay, well I need to move up the ladder. I'm gonna be a people manager," and then their next step is people management. And they're like, "This sucks. Like I, nobody told me about like all the things I have to deal with and the people." And you're still in the mindset of like box checking, of like, in order to be successful, "I have to do all these things. I have to do X, Y, and Z." And I think that the second I stopped checking all the boxes and trying to do all the things was when I went from being like a manager to an actual leader of people and activating them. And if I could just get a few people who I believe, like I've even seen so many really great people leave the industry because they feel like they want to advance, but they don't see because they weren't a good manager, like, "Well, how would I ever be a good director or a good VP," or so on and so forth. The reality is like probably the hardest transition is going from independent contributor to a manager, and yet it's like the least supported space. So that's I think that's something I feel deeply passionate about and would love to like able to offer as a resource more for people. [00:32:10] Lindsey Dinneen: And that would be an incredible masterclass. Okay, and then how do you wish to be remembered after you leave this world? [00:32:18] Logan McKnight: I love that one. I mean, I think at the end of the day, that's the impact thing. You know, and I don't even think it has to be this, like, big, you know, like, "Oh, I, you know, solved healthcare in Ghana." Like, you know, it's not that. It's almost like I, I hope that like my company and my interaction with people leaves everyone feeling a little lighter, a little happier, like a little more capable to do like something, and they feel like talking with me, working with me has unlocked like the next level of something that they've been struggling with and makes them feel like, "Okay, I can do this now." 'Cause I almost feel like that's what, what coaching and consulting comes down to is I'm not doing the thing for anybody. I am only helping to remove the roadblock around them, that they stop limiting themselves and they really see what's possible just by making a few changes in the way they think, in the way they operate their business or run their team. And, you know, amazing things happen. So my hope is that I just continue to get to do that and have people that really feel positive impact from that. [00:33:26] Lindsey Dinneen: Yeah. Well that is a beautiful legacy, so, yeah. All right. And then final question. What is one thing that makes you smile every time you see or think about it? [00:33:38] Logan McKnight: Oh, gosh. Well, we just talked about this before our call, but my dog, I have, I'm an animal lover, and so I have the fortune that every day, most every day I'm in my home office and I get to go on a hike or walk with my dogs, either around our property or out somewhere in beautiful Washington. And I think just like seeing the mountains and being out with my dog, like that just makes me smile. And I think it's also what inspired me to paint and all the things. So I, I think just all the beauty like in the world just makes me smile and makes my heart very happy. [00:34:12] Lindsey Dinneen: I love that. Oh my goodness. That's beautiful. All right, well this has been an amazing conversation, Logan. I so appreciate you and your time today. And we're so honored to be making a donation on your behalf as a thank you for your time today to the American Society for the Prevention of Cruelty to Animals, which is dedicated to preventing animal cruelty in the United States. So thank you for choosing that organization to support and we just wish you continued success as you work to change lives for a better world. [00:34:43] Logan McKnight: Yeah, thanks for having me. We'll talk soon. [00:34:45] Lindsey Dinneen: Sounds good. Thank you and take care. [00:34:49] Dan Purvis: The Leading Difference is brought to you by Velentium Medical. Velentium Medical is a full service CDMO, serving medtech clients worldwide to securely design, manufacture, and test class two and class three medical devices. Velentium Medical's four units include research and development-- pairing electronic and mechanical design, embedded firmware, mobile app development, and cloud systems with the human factor studies and systems engineering necessary to streamline medical device regulatory approval; contract manufacturing-- building medical products at the prototype, clinical, and commercial levels in the US, as well as in low cost regions in 1345 certified and FDA registered Class VII clean rooms; cybersecurity-- generating the 12 cybersecurity design artifacts required for FDA submission; and automated test systems, assuring that every device produced is exactly the same as the device that was approved. Visit VelentiumMedical.com to explore how we can work together to change lives for a better world.

Are you a real estate investor? If so, don't miss out on potential tax savings. In today's episode, Gian Pazzia joins Russ and Joey to discuss the benefits of cost segregation and why you should apply it before filing your 2026 taxes. Learn how to accelerate deductions, maximize your savings, and reduce your tax bill, all while taking advantage of new tax laws.Gian walks us through a detailed case study showing how someone can potentially save tens of thousands of dollars in taxes by doing a cost segregation study in their first year of owning property. He also shares insights on who should apply for cost segregation, the potential risks of missing out on deductions, and how this tax strategy works for different types of properties.Whether you're a seasoned investor or just getting started, this episode could help you take control of your tax situation and make smarter financial decisions.Top three things you will learn:-How cost segregation can help real estate investors save thousands in taxes-The difference between traditional depreciation and accelerated deductions through cost segregation-Who should and shouldn't use cost segregation, including key strategies for short-term rental investors and passive income earnersAbout Our Guest:Gian P. Pazzia is currently the Chairman & Chief Strategy Officer at KBKG and oversees all strategic initiatives for the company. He has over 25 years of experience in the specialty tax industry.Before joining KBKG, Gian worked at two of the Big Four accounting firms. At PWC in Chicago, he served on the National Cost Segregation Consistency Committee, where he was responsible for the development of their proprietary cost segregation software. He also developed their first in-house advanced engineering training program.Gian served as the President (2013-2015 term) of the American Society of Cost Segregation Professionals (www.ASCSP.org) and held a seat on their Board of Directors for a decade.Disclaimer: The opinions expressed on this podcast are solely those of the hosts and guests and do not constitute financial advice. Always consult a licensed professional for financial decisions.This episode is sponsored by a podcast show partner. We may receive compensation if you use links or services mentioned in this episode.The hosts may have a financial interest in the programs or services mentioned in this episode.Connect with Gian Pazzia:- Website - https://www.costsegregation.com/ (10% off for WWWS Podcast listeners with promo code WITHOUTWALLSTREET at checkout on their website)

The legal landscape for peptide therapy is changing. In this episode, Dr. Greg Jones talks with healthcare attorney Jeff Cohen about recent regulatory updates and their implications for providers. Jeff explains the risks of using "Research Use Only" products in a clinical setting and how to properly verify your suppliers' quality and safety. You will learn why it is important to focus on education rather than promotion on your website and how to improve your informed consent process to protect your license. Jeff also discusses the goals of the new American Peptide Association in setting industry standards. This conversation provides clear steps for clinic owners and practitioners to stay compliant while using compounded medications.

This week's show features stories from Radio Deutsche-Welle, France 24, Radio Havana Cuba, and NHK Japan. http://youthspeaksout.net/swr260306.mp3 (29:00) From GERMANY- Three short statements- the first from Prof Fawaz Gerges from the London School of Economics, a tech scientists explaining the role of AI in the attacks on Iran, and Aya Ibrahim, DW Head of Current Affairs, on the false perception that the Gulf States are a monolith. From FRANCE- The press reviews were informative all week but we will listen to Monday stories from the Middle East and Europe on the war on Iran. Trump threatened Spain after they refused the US military use of their bases, and President Sanchez replied. The US oil and fuel embargo on Cuba has left them with little electricity, no radio or television, and almost no transportation. From CUBA- Mexican President Sheinbaum reaffirmed her countrys commitment to supply aid to Cuba. The 10th anniversary of the murder of Honduran indigenous environmental activist Berta Caceres was acknowledged by Cuba. On Monday the Secretary of Iran's Security Council reminded the world that his country did not initiate the war with Israel and the US, which began shortly after mediators hailed a breakthrough with Iran agreeing to zero stockpiling of uranium at talks in Geneva. From JAPAN- Japan is considering burying high level radioactive waste in an island their most eastern holding in the Pacific Ocean. French President Macron announced plans to increase his countrys number of nuclear warheads- France currently has 290 nuclear weapons. The Chinese Foreign Minister discussed the war on Iran with the Iranian Foreign Minister. The death toll of the schoolgirls in the missile strike in Iran rose to 171. The American Society of International Law has expressed concern about the Israel/US war now expanding across the Middle East. A UN fact finding mission has stronly condemned the US/Israeli strikes on Iran, calling for an immediate halt to attacks by all parties. Available in 3 forms- (new) HIGHEST QUALITY (160kb)(33MB), broadcast quality (13MB), and quickdownload or streaming form (6MB) (28:59) Links at outfarpress.com/shortwave.shtml PODCAST!!!- https://feed.podbean.com/outFarpress/feed.xml (160kb Highest Quality) Website Page- < http://www.outfarpress.com/shortwave.shtml ¡FurthuR! Dan Roberts "Historically, the most terrible things - war, genocide, and slavery - have resulted not from disobedience, but from obedience." --Howard Zinn Dan Roberts Shortwave Report- www.outfarpress.com YouthSpeaksOut!- www.youthspeaksout.net

Dr. Michele Shermak is on a mission to clear up the confusion surrounding plastic surgery. With med spas on every corner and social media full of mixed messages, she's passionate about making sure patients get the right information from the right sources.That passion led her to chair the American Society of Plastic Surgeons' Public Education Committee, where she's elevating patient education across the board.Dr. Shermak breaks down what sets board-certified plastic surgeons apart, from the focus on safety and credentials to the importance of finding a provider who truly listens.She also opens up about the challenges of teaching multiple generations, her favorite creative ways to share trustworthy information, and how platforms like Instagram are shaping the next wave of patient education.As AI revolutionizes aesthetics, Dr. Shermak shares both excitement and caution about how tools like chatbots might change medical education and communication—and why accuracy and privacy still come first.Recorded live at the ASPS Annual Meeting in New Orleans.About Dr. Michele ShermakDr. Michele Shermak is a board-certified plastic surgeon, widely regarded for her exceptional patient care and meticulous, individualized approach to aesthetic and reconstructive surgery. She's internationally recognized for her expertise in breast and body contouring, combining innovative techniques, compassion, and clear communication to ensure every patient feels confident and supported from consultation through recovery. Dr. Shermak sets the standards for excellence as a director on the American Board of Plastic Surgery, and focuses on patient safety, natural results, and personal connection throughout every procedure.Learn more about Baltimore plastic surgeon Dr. Michele ShermakFollow Dr. Shermak on Instagram @micheleshermakmdGuestMichele Shermak, MDPlastic surgeon in Baltimore, MarylandHostRobin Ntoh, VP of AestheticsNextechPresented by Nextech, Aesthetically Speaking delves into the world of aesthetic practices, where art meets science, and innovation transforms beauty.With our team of experts we bring you unparalleled insights gained from years of collaborating with thousands of practices ranging from plastic surgery and dermatology to medical spas. Whether you're a seasoned professional or a budding entrepreneur, this podcast is tailored for you.Each episode is a deep dive into the trends, challenges, and triumphs that shape the aesthetic landscape. We'll explore the latest advancements in technology, share success stories, and provide invaluable perspectives that empower you to make informed decisions.Expect candid conversations with industry leaders, trailblazers and visionaries who are redefining the standards of excellence. From innovative treatments to business strategies, we cover it all.Our mission is to be your go-to resource for staying ahead in this ever-evolving field. So if you're passionate about aesthetics, eager to stay ahead of the curve and determined to elevate your practice, subscribe to the Aesthetically Speaking podcast.Let's embark on this transformative journey together where beauty meets business.About NextechIndustry-leading software for dermatology, medical spas, ophthalmology, orthopedics, and plastic surgery at https://www.nextech.com/ Follow Nextech on Instagram @nextechglowAesthetically Speaking is a production of The Axis: theaxis.io Theme music: I've Had Enough, Snake City

In this episode, we welcome legendary sound mixer and CAS President Peter Kurland, CAS. Peter is a BAFTA-winning, Grammy-winning, 4x Oscar-nominated, and 3x CAS Award-winning Sound Mixer who's worked on films such as Blood Simple, Hoosiers, Raising Arizona, Barton Fink, Fargo, Men in Black, The Big Lebowski, O Brother Where Are Thou, The Man Who Wasn't There, Walk The Line, No Country for Old Men, A Serious Man, True Grit, Inside Llewan Davis, and The Tragedy of Macbeth. In our conversation, Peter shares his origin story, about his decades-long collaboration with the Coen Brothers, and stories from capturing sound on set. He also offers insights and advice for the next generation of artists and storytellers today. “The Making Of” is presented by AJA:Butcher Bird Studios solves common video routing and I/O challenges with AJAStep inside Butcher Bird Studios' hybrid production environment with Technical Director Brian Druckman and Executive Producer MeeRa Kim. They explain how KUMO SDI routers and Io 4K Plus help their team deliver flexible routing, low-latency monitoring, and streamlined I/O inside and outside the studio. Read the full interview.Kodak Celebrates Kristen Stewart, Autumn Durald Arkapaw, Joachim Trier and Patricia Keighley at the 8th Annual Kodak Film AwardsChristopher Nolan Presents Inaugural Keighley Award at ASC Clubhouse CeremonyOn March 2, Kodak hosted the 8th Annual Kodak Film Awards at the American Society of Cinematographers (ASC) Clubhouse in Hollywood, honoring filmmakers and artists whose work continues to advance cinematic storytelling on film. 2026 Honorees included: Debut Feature Award: Kristen Stewart (presented by Corey C. Waters, Director of Photography), Lumière Award: Autumn Durald Arkapaw (presented by Vanessa Bendetti, VP and Head of Motion Picture, Kodak), Auteur Award: Joachim Trier (presented by Jason Reitman, Director), Keighley Award: Patricia Keighley of IMAX (presented by Christopher Nolan, Director, Producer and Screenwriter), Music & Commercial Film Director Award: Salomon Ligthelm (presented by Ali Brown, PRETTYBIRD President/Executive Producer), Television Series of the Year: Fallout (presented by Vanessa Bendetti, VP and Head of Motion Picture, Kodak). Read more hereLos Angeles Event: ZEISS Aatma Lenses - A Conversation with Pascale Marin, AFCTuesday, March 10th | Los AngelesJoin ZEISS Cinema at the Showroom for an in-depth discussion and demo of the new ZEISS Aatma cinema lenses. Director Helene de Roux and cinematographer Pascale Marin, AFC will be on hand to discuss their experience using the lenses to craft the short film Welcoming Grace. Join us from 6pm-9pm on March 10th to be one of the first to experience this unique lens family from ZEISS!RSVP for free hereAttendees will receive free parking validation.Now with Massive 8TB Capacity—Thunderbolt 5 SpeedThe OWC Envoy Pro Ultra now comes in a new 8TB capacity, pairing enormous space with next‑generation Thunderbolt 5 performance. With real‑world speeds over 6000 MB/s and a rugged, bus‑powered design, it's perfect for 4K/8K workflows, on‑location shoots, and fast media offloads. High‑speed, high‑capacity, and ready for serious creative work. Browse hereA New Solution from Atomos:The Atomos Shogun AV-19 Rack-Mounted 4K HDR Monitor/Recorder/Switcher is your all-in-one solution for professional live production, combining a stunning 19” 4K HDR DCI-P3 display with quad-channel switching, real-time ISO recording of up to four camera feeds plus program out, and support for 10-bit Apple ProRes, ProRes RAW, and Avid DNx recording to CFexpress or USB-C media. Perfect for studios, video village, and broadcast environments, it delivers the monitoring accuracy and workflow efficiency your production demands. The Atomos Shogun AV-19 is available for pre-order now for $2,099.00. Learn more at Videoguys.com or call our production experts at 800-323-2325 today!Advertise in The Making Of:Feature your products or solutions in The Making Of and reach over 250,000 film and TV industry each week.To explore a partnership, please email mvalinsky@me.comPodcast Rewind:Feb. 2026 - Ep. 122. Get full access to The Making Of at themakingof.substack.com/subscribe

According to expert Erica Keswin: The human stuff is the hard stuff, even and especially with AI changing our workplaces. Learn more from Erica about what's needed from human leaders today and for the future of work. Recorded at APC 2025 and produced by the American Society of Administrative Professionals - ASAP. Learn more and submit a listener question at asaporg.com/podcast.

Dr. Deb Muth 0:00 Welcome back to Let’s Talk Wellness Now. I’m your host, Dr. Zab, and we are continuing our discussion this week on 0:08 peptides. And so, if you haven’t heard our first conversation about peptides, 0:13 please go back and look at that episode. We talk all about the manufacturing, the safety, the quality of peptides, and we 0:20 dove into GLP1s. And today we’re going to dive into peptides for sexual 0:26 wellness, immune function, growth hormone, and all the amazing fun things 0:32 we can do with peptides. So, as usual, grab your cup of coffee or tea, settle 0:37 in, and let’s talk wellness now. And we’re going to take a short pause from our sponsor. I know we’ve got to do 0:44 that, you guys. They’re who keep us on the air. So, I’m going to pause for just a minute and be right back after this 0:50 message from our sponsor. Ladies, it’s time to reignite your vitality. Primal 0:56 Queen supplements are clean, powerful formulas made for women like you who want balance, strength, and energy that 1:03 lasts. Get 25% off at primal queen.com. Serenity Health. That’s primalqueen.com. 1:10 Serenity Health. Because every queen deserves to feel in her prime. All 1:15 right, everybody. We are back. And are you ready? We are talking all things peptide and I am opening the show today 1:23 with sexual wellness. Yes, I’m going there, you guys. I am going there. You 1:29 know, this has really become a big issue for people um of all ages. It’s not just 1:3 4us older people. It’s younger people, too. And there’s a whole variety of reasons why we have sexual dysfunction. 1:42 And when we’re talking about sexual dysfunction, we’re not just talking about it doesn’t work, right? Or I can’t 1:48 reach orgasm. A lot of it is around desire and um the thought of it and 1:54 wanting to connect, wanting to be kinder to one another, wanting to be touching 2:00 one another. A lot of it resolves or revolves around that. And so there are some peptides that can help us and I’m 2:08 really excited to be able to talk about those today. So the first one is called PT-141. 2:14 This targets the brain not the periphery. Right? So for many women I 2:20 will always tell you sex starts between here. It is a brain thing for us. It is 2:26 not necessarily a physical thing. For guys that’s a little different. It’s very physical. For women it’s all in our 2:32 brain. So tip for you men that are listening. You have to prime your woman’s brain first if you want her to 2:38 have sex with you that night. You have to be nice to her. You have to bring her flowers. Do the dishes for her. Do 2:45 something kind. Bring her a cup of coffee or tea or a glass of wine. Take her to dinner. You have to woo her. And 2:51 I don’t care how long you’ve been married. That has to happen. And tip number two, don’t say anything stupid 2:57 that day. I’m just being honest. When you guys say things that make us upset, 3:03 that lingers with us for the rest of the day. And it’s it’s a turnoff for us. And 3:08 for a lot of women, we can’t get past that when it comes time to snuggle at night. And sex doesn’t always have to be 3:14 at night either. So, you can tell I really love talking about this conversation, but we’re going to get into the peptide part of it because this 3:21 is going to help people. So, um, PT-141 is marketed as I’m going to slaughter 3:28 this name, Vali, and it represents a fundamentally different approach to 3:34 sexual dysfunction than the PDE5s inhibitors like Slenden, Viagra, 3:40 Tedataphil, which is Seialis. And while the PDE5 inhibitors work specifically by 3:47 enhancing blood flow to the genital tissues, PT-141 works centrally in the brain by 3:54 modulating neural s neural circuits involved in the sexual desire and 4:00 arousal. Now PT-41 is a cyclic hpatipeptide. It’s seven amino acid 4:07 peptide arranged in a cyclic structure that acts as a melanoortin receptor 4:13 agonist and with particularly the infinity for MC3R and MC4R subtypes. 4:20 It’s actually a metabolite of the melanotan 2, a peptide originally 4:26 developed for tanning that was also found to enhance sexual desire in early 4:31 studies. Now the melanoortin system in the brain is involved in multiple functions including energy homeostasis 4:39 but it also is involved in sexual motivation and arousal behaviors. The FDA approved PT-141 in 2019 specifically 4:48 for the treatment of acquired generalized hypoactive sexual desire 4:54 HSDD in permenopausal women. So for the first time we have a medication that was 5:01 approved by the FDA to use for women for sexual dysfunction. We have had all of 5:07 these seialis tedataphil viagros for men but we had nothing for women. And so 5:12 this is amazing that this is available for women and approved by the FDA. It’s a big deal. This represents the first 5:19 and only FDA approved medication specifically targeting these circuits of sexual desire rather than the peripheral 5:27 arousal mechanisms. And this indication is quite specific, meaning it was developed at some point, not lifelong. 5:35 So I if you’ve had sexual dysfunction your entire life, this medication was 5:40 not approved for you. But if it’s something that you developed over time, like when you went through pmenopause or 5:46 menopause or some women have this experience happen after childirth, that’s what we’re talking about here. 5:53 Now, it’s also not just um supposed to be used if you dislike your partner, 5:59 right? If your relationship is bad and you dislike your partner, this probably isn’t going to fix a ton. It might help 6:05 a little bit, but that’s not what it’s meant for. So, you really have to know what you’re using it for and why. And 6:11 the other thing that I would say is this is something that we don’t go to if your hormones are not balanced properly. You 6:17 have to balance your hormones properly before using something like this because it still may not work. Now, the only 6:24 caveat to that is if you’re a woman that has a risk of breast cancer and can’t use hormones, then that’s a different 6:31 story and we would have that conversation about whether or not this medication would be appropriate for you. Now, the FDA label specifies PTA1 uh 6:39 PT-141 as it not being indicated for HSDD in causes where low sexual desire 6:46 is due to coexisting medical or psychiatric conditions, problems with relationships, like we had talked about, 6:53 side effects to medications or other substance use. This specifically reflects the importance of differential 6:59 diagnosis. Low sexual desire can have many root causes and PT-41 is only 7:05 appropriate when those causes have been ruled out. Now, I have I used PT41 in 7:10 people who have sexual dysfunction issues as a result of using 7:16 anti-depressants. Yes, I have. I’ve used Flynn in that effect as well. And it 7:21 does work sometimes, but it doesn’t work completely. But you need to know that that is not what the approval is for the 7:27 FDA. So that is done in something that we call off label use. So very important 7:33 to know. Now in these clinical trials leading to FDA approval, this was published by Kinsburg and colleagues in 7:40 obstetrics and gyne gynecology in 2019. PT-141 demonstrated statistically 7:46 significant improvements in sexual desire and decreases in distress related 7:51 to low desire compared to placebo. The effects manifest over 45 minutes to 7:56 several hours after the injection and the mechanisms involved modulation of dopamine and melanoorton pathways in the 8:04 hypothalamus and the brain regions that involved sexual motivation. Now cardiovascular effects of PT 141 require 8:12 careful attention. This drug causes transient increases in blood pressure about 3 to four points and transient 8:20 decreases in heart rate. And because of this, it is contraindicated in patients 8:25 with uncontrolled hypertension or known cardiovascular disease. And it has been studied in patients who’ve had recent 8:32 cardiovascular events or sorry hasn’t been studied hasn’t been studied in patients who’ve had recent 8:39 cardiovascular events. So patients need to have their blood pressures checked before starting therapy. Nausea is 8:45 extremely common. It is one of the biggest things I often will tell people to take an anti-nausea medicine if 8:52 they’re going to do this because the last thing you want to do is inject this medication and think it’s going to give 8:57 you this great time with your partner and you’re so nauseated that you can’t even perform, don’t want to kiss, don’t 9:05 want to do anything. It it can be pretty profound for some people. um it does affect about 40% of the patients in 9:12 clinical trials which is why many clinicians require or recommend an 9:17 anti-nausea medication like I had just said other common adverse effects include flushing injection site 9:24 reactions headache in about 13% of the population which I have seen worse if 9:30 people are prone to headaches and the headaches are pretty intense so I will also have them premedicate if they have 9:36 that um sensitivity ity with a Tylenol or Advil, Alie, whatever it is they 9:42 typically use for their headaches to help prevent that from occurring. Now, some patients also experience a 9:50 generalized hyperpigmentation of their skin, particularly in areas with chronic friction, and this may not be reversible 9:57 after discontinuation. So from an integrative perspective, PT-41 10:03 represents one tool in addressing female sexual dysfunction, but it should never be the first or only intervention. And 10:11 low sexual desire in women is complex. Multiffactorial involving hormonal imbalances, low testosterone, estrogen 10:18 deficiency, progesterone imbalances, thyroid dysfunction, adrenal dysfunction, and with elevated or 10:24 disregulated cortisol levels, sleep deprivation, relationship issues, unresolved trauma, including sexual 10:31 trauma, chronic pain, body image concerns, and medication side effects such as SSRIs are notorious for this. So 10:39 a comprehensive hormone panel including total and free testosterones, estradile, 10:45 progesterone, DHEA, thyroid function in cortisol assessment, ideally four-point 10:51 cortisol, salivary should precede any pharmacological intervention. And additionally, addressing the 10:57 psychological component and relationship dimensions through appropriate therapy is necessary. I have a lot of patients 11:03 that say, “This is just too much work for sex. I don’t want the side effects. I don’t want to deal with this.” and that’s totally fine. But for some 11:09 people, their sexual dysfunction is actually causing more problems on their 11:14 relationship and they want to do something to fix that. And just know that if you’re using a peptide like this 11:20 that comes with some of these side effects and you have to premedicate for it, it is not the end of the world. Um, 11:27 but it may be a possibility that you may need that. So, let’s dive into body composition and growth hormone access. 11:34 So Tesmarellin is the only FDA approved GH 11:40 analog. Tesarelin is marketed as Agrifta and Agria SV. It is a synthetic analog 11:48 of human growth hormone releasing hormone. So GH RH human growth hormone 11:53 releasing hormone. These things are such long names it’s confusing and it’s difficult to spit out, right? It 11:59 consists of 44 amino acids. The structure is identical to our own 12:05 body’s growth hormone GHR um with the addition of trans3 hexonol group which 12:14 stabilizes the molecule that extends its half-life compared to the native GHR. 12:19 The mechanism of tesmarellin is elegant in its preservation of physiological 12:24 growth hormone GH secretion patterns and rather than administering an exogenous 12:30 growth hormone directly, tesmarillin binds to the GH receptor in the anterior 12:36 pituitary gland stimulating the indogenous pulsatile release of GH. So 12:42 you know it it’s slower in that stimulation and it pulsates instead of a direct rise and fall. This pusile 12:49 pattern more closely mimics natural GH secretion which occurs in bursts 12:54 primarily during sleep. The GH then stimulates the liver to produce insulin-like growth factor IGF-1 which 13:01 exerts many of the downstream metabolic effects including lipolytic effects on 13:07 the atapost tissue. So fat atapose and how we break that down. The FDA approved 13:13 tesmarellin in 2010 for a very specific narrow indication, the reduction of 13:19 excess abdominal fat in HIV infected patients with lipodistrophe. This 13:25 condition characterized by abnormal fat redistribution with accumulation of visceral body fat and the loss of 13:32 subcutaneous fat in face and limbs developed as a complication of an 13:37 antiviral therapy particularly with older protease inhibitor reg uh 13:42 regimens. The visceral fat accumulation in patients is not just cosmetic. It’s associated with increased cardiovascular 13:49 risk, insulin resistance, and inflammatory markers. The pivotal trial that led to the FDA approval included 13:56 work by Stanley and colleagues published in the annuals of internal medicine in 2014. It demonstrated that tesmarillan 14:03 significantly reduced the visceral atapose measured by CT scan by approximately 15 to 20% which is a 14:10 significant difference to placebo over a short period of time only 26 weeks. Now, 14:16 interestingly, the total body uh weight typically remained stable or even 14:21 increased slightly as the reduction of visceral fat was sometimes offset by increases in lean body mass or 14:28 subcutaneous fat. This highlights an important point. Tesmearellin is not a weight loss drug in its conventional 14:34 sense. Its effects are specifically on body composition and fat redistribution. 14:40 Now the glucose metabolism effects of tesmarellin do require careful monitoring because GH and IGF1 can 14:47 induce insulin resistance. Tesmearellin can increase glucose levels and hemoglobin A1C and in these clinical 14:54 trials glucose tolerance and new onset diabetes occurred in some patients. So 14:59 this creates a therapeutic paradox while res reducing visceral fat we should theoretically improve metabolic health. 15:07 The GH mediated insulin resistance can worsen the glycemic control and patients 15:12 with diabetes require particularly close monitoring. The potential need for adjustment in diabetic medications can 15:19 occur. So I already know what you guys are thinking. Can I use Tesmarellin and 15:24 GLP1 at the same time? And the answer is yes. Especially in those people that we 15:30 know have an insulin resistance already or are prone to that, we can use lowd 15:36 dose micro doing GLP-1 along with tesmarellin to help prevent this from 15:42 occurring um or reduce the risk of it occurring. Now there are some other adverse related problems to growth 15:49 hormone access which include fluid retention which can uh manifest as uh 15:55 ankle swelling, joint pain, muscle pain, paristhesas, carpal tunnel syndrome is 16:01 common to see. Of course you can always see injection site reactions reported about 26 to 30% of the time in the trial 16:08 participants. And this also theoretically has a concern about IGF-1 elevation potentially promoting 16:14 malignancy through long-term data is limited. So we have to be cautious about 16:20 this but it is a growth hormone and anything that is a growth hormone can cause cells to grow and it cannot 16:26 necessarily differentiate between healthy cells and bad cells. So the drug is contraindicated is contraindicated in 16:33 patients with active cancer and in patients with the disruption of the HPA access from conditions like pituitary 16:40 tumors, pituitary surgery, head of radiation um and traumatic brain injury. 16:46 Now off label use of tesmarellin for general anti-aging or body composition 16:51 optimization in non-HIV population, it doesn’t have FDA approval. There is no 16:58 FDA studies. um that promote this, but practitioners do prescribe it for these 17:04 purposes under an experimental and not supported by FDA approved indications. 17:10 And um from an integrative medical standpoint, optimizing natural growth 17:15 hormone secretion through lifestyle interventions, high quality sleep is important. GH primarily is excreted 17:22 during sleep and deep sleep waves. So improving your deep sleep is important. Intermittent fasting can also increase 17:28 growth hormone by five-fold as demonstrated in a Hartman and colleagues uh study from the journal of clinical 17:35 endocrinology and metabolism in 1992. And highintensity interval training, adequate dietary protein, blood sugar 17:42 control, these all can help naturally increase your growth hormone. So, let’s 17:47 dive in now and talk about bone health. peptide hormones um such as oh I’m gonna 17:54 I’m gonna really slaughter this name. Terraparatide is a true bonebuilding 18:01 peptide. It’s marketed as forio. It’s a recumbent form of the first 34 amino 18:08 acids out of 85 of the human parathyroid hormone PTH. It represents a unique 18:13 approach to osteoporosis treatment because it’s one of the few truly anabolic anabolic bone therapies meaning 18:21 it actively binds new bone rather than simply preventing bone loss. The biology 18:26 of parathyroid is fascinating and seemly contraindicated or uh contradictory. 18:32 Continuously sustained elevations of PTH as occurs in hyperarathyroidism 18:37 is catabolic to bone. So people who have hyperarothyroidism typically have significant bone loss 18:44 especially before it’s diagnosed and it causes causes increased bone 18:49 reabsorption loss of bone density increased fracture risk and however 18:55 intermittent exposure to PTH as achieved with once daily uh injections of forio 19:01 has the opposite effect. This intermittent exposure preferentially stimulates osteoblasts bone building 19:08 cells over osteoclasts bone reabsorbing cells and it leads to 19:13 the net bone formation. So terraparatide binds to the PTH receptors on 19:20 osteoblasts and renal tubular cells in bone. It increases the number of 19:25 activity of osteoblasts stimulating the differentiation of osteoblast precursor cells and may 19:32 reduce osteoblast apoptosis basically programmed cell death allowing this bone 19:37 building cell to work longer. The result is increased bone formation, improved bone architecture and tbacular 19:45 connectivity and ultimately increased bone mineral density um particularly in the hip and the spine which is so 19:51 difficult to regain. The FDA approved this medication in 2002 based on pivotal 19:57 studies by Near and colleagues published in the New England Journal of Medicine in 2001 which demonstrated significant 20:05 reductions in vertebral and non-vebral fractures in post-menopausal women with 20:11 osteoporosis. specifically uh reduced new vertebral fractures by 20:17 65% and nonvettebral fragility fractures by 53% 20:23 compared to placebo over a median followup of 21 months. This is really 20:29 incredible because we have not seen this kind of um change uh in other 20:35 medications that we’ve used for osteoporosis. So current FDA approval 20:40 indicates uh this for post-menopausal women with osteoporosis at high risk for 20:46 fracture, men with primary or hypoconatal osteoporosis at high risk for fracture 20:53 and men and women with glucocord cord glucocordide 21:00 induced osteoporosis at high risk for fracture. The high risk qualifier is 21:05 important. uh terrapeptide is reserved for patients with severe osteoporosis, 21:11 multiple fractures, very low low bone density and those who have failed or are 21:16 intolerant of other therapies. The most significant concern for this medication 21:21 is highlighted in a boxed warning with rat toxicology studies where it caused 21:27 osteioaroma which is a bone cancer in a dose dependent and treatment duration dependent manner. The revolence of this 21:34 finding to humans is debated. Rats have fundamentally different bone biology than humans with continuous bone growth 21:41 throughout life and different PTH receptors. Now post marketing 21:46 surveillance in humans hasn’t shown a clear increase in osteocaroma risk but 21:51 theoretically concerns persist and because of this terapeptide is 21:57 contraindicated in patients at risk baseline risk for osteioaroma 22:02 including those with pageantss disease of the bone unexplained elevations of alkaline phosphate prior skeletal 22:10 radiations bone metastases or skeletal malignancies and pediatric patients or young adults 22:16 with open hyes. There’s also a lifetime treatment duration of only 2 years and 22:22 terrapeptide can cause transient hypercalcemia. So an elevated blood calcium and as PTH normally increases 22:31 calcium levels by enhancing bone reabsorption, increasing renal calcium 22:36 reabsorption and promoting activation of vitamin D which increases intestinal calcium absorption. Some patients 22:43 experience orthostatic hypotension within 4 hours of injecting requiring 22:48 caution in at risk populations for blood pressure. Common side effects include 22:53 muscle pain, joint pain, pain in the limbs, nausea, headache, and dizziness. So from an integrative bone health 23:00 perspective, terrapeptides should be part of a comprehensive strategy. Adequate calcium intake, 500 to a,000 23:08 milligrams of calcium a day from food and supplements combined. and vitamin D. 23:13 Getting vitamin D levels of at least 50 to 80 are essential for the drug to work 23:20 optimally. But beyond this, bone health requires vitamin K2, which directs calcium into the bones rather than soft 23:27 tissues, magnesium as a co-actor in bone metabolism, trace minerals like boron, 23:33 copper, silica, and of course, adequate protein intake, which many of us, especially as women, don’t do 0.8 8 to 1 23:42 gram of protein per kilogram of body weight, weightbearing exercise. Of 23:47 course, these all provide mechanical signals that complement the biochemical 23:52 symbol uh signals of terrapeptide. Sequential therapy is also critical. The 23:58 bone mass gains from terraparatide can be lost if patients don’t transition to 24:05 an anti-resorbbitive agent a bisphosphinate after completing this therapy and the anabolic effects to 24:12 build bone but maintaining the new bone requires preventing excess reabsorption. 24:18 So positive things about this but there are definitely some concerns as well. So 24:23 the next one we’re going to talk about is Lu Prolrooide. It is marketed under 24:29 the multiple brand names of Lupron, Depo, Eligard, and it’s a synthetic 24:34 nonapeptide analog of naturally occurring ginonadotropen releasing 24:39 hormone G&R, also called luteinizing hormone releasing hormone, LHR. 24:46 It’s a fascinating example of how manipulating natural hormonal feedback systems can create therapeutic effects. 24:53 So, G&RH is normally secreted in a pulsatile fashion by the hypothalamus 24:59 and travels to the anterior pituitary where it binds to G&R receptors and 25:05 stimulates the release of luteinizing hormone LH and follical stimulating hormone FSH. These ginatotropins signal 25:13 the ovaries or the testes to produce sex hormones, estrogen, progesterone in 25:18 women, testosterone in men. Uh, luoprololi lupron as a GNR agonist 25:26 initially mimics the action of natural G&R causing an acute flare response with 25:33 uh increased LHFSH secretion which temporarily increases sex hormone 25:38 production. However, the continuous administration which is in the depo 25:44 formulations, the GNR receptors in the pituitary become desensitized and 25:50 downregulated. And after about 2 to four weeks of continuous exposure, LH and FSH 25:56 secretion is profoundly suppressed, leading to what’s termed as chemical 26:01 castration. Testosterone levels in men drop to castrated levels less than 50 26:08 and estrogen production is marketkedly suppressed in women. This bifphasic 26:13 response creates both therapeutic applications and management challenges in prostate cancer where tumor growth is 26:20 typically androgen dependent and the ultimate goal is testosterone suppression. However, the initial 26:27 testosterone surge during the flare phase can temporarily worsen symptoms potentially causing increased bone pain, 26:34 urinary obstruction, or even spinal cord compression in patients with metastatic 26:40 disease. This is why uh luoprolide is often started with an anti-ad androgen 26:47 like bicladamide for the first two to four weeks to block the effects of the 26:52 testosterone surge. The FDA has approved lupalide for multiple indications across 26:59 formulations. In oncology, it’s used for palletive treatment of advanced prostate cancers. In gynecology, various 27:06 formulations are approved for endometriosis, for pain management and lesion reduction and for fibroids. 27:13 Typically for pre-operative uh hematological improvement in anemic patients. In pediatrics, it’s used for 27:20 central precocious p puberty basically to halt the premature sexual development of these young people. Now, there are 27:28 adex uh adverse effect profile that reflects profound hormonal suppression. 27:34 In men treated for prostate cancer, hot flashes affect about 59% of the patients. Other common effects include 27:41 general pain, swelling, bone pain. Um long-term use of these medications leads 27:47 to metabolic changes. It increases fat mass. It decreases lean mass. It worsens 27:53 insulin sensitivity, disrupts the cholesterol uh lipid panels, increases 27:59 diabetic risk, has some concerns over cardiovascular disease. And the metaanalysis have shown increased risks 28:06 of heart infarction, myocardial inffection, sudden cardiac death, and stroke in populations receiving 28:13 long-term androgen deprivation therapy. The bone effects are particularly dramatic. Without sex hormones, bone 28:20 density decreases significantly, typically 3 to 4% per year during the 28:26 first two to three years of therapy. And this bone loss may not fully be reversible after the the therapy 28:32 discontinues. The American Society of Clinical Oncology recommends bone density monitoring and consideration of 28:39 bisphosphinates uh in men receiving long-term androgen deprivation. In women treated for 28:46 endometriosis or fibroids, the estrogen suppression creates a hypoestrogenetic state similar 28:54 to menopause. Hot flashes affect 90% of patients with other common effects 29:00 including headaches, emotional irritability, decreased sex drive, vaginal dryness, bone density loss. And 29:08 because of these bone concerns and treatment duration with endometriosis, typically limited to six months, though 29:14 some formulations allow for longer use with adback hormonal therapy to 29:20 partially mitigate these side effects. The mood and cognitive effects can be s 29:25 significant. I’ve seen it over the years. the depression, the memory impairment, difficulty focusing and 29:31 concentrating. It can be very very traumatic and the quality of life that 29:37 happens for these uh women and men can be unbearing for many of them. Um, from 29:44 an integrative perspective, patients receiving this medication need comprehensive support care. Bone health 29:51 interventions using calcium, vitamin D, vitamin K2, weightbearing exercise, 29:58 cardiovascular risk management becomes critical, including blood pressure monitoring, lipid management, diabetes 30:05 screening. For hot flashes management, some patients respond to black coohos, 30:10 sage, or vitamin E. Though evidence is mixed and individual response varies, 30:16 omega-3s may help with the mood and the inflammation, resistance training becomes specifically important to 30:22 preserve lean muscle mass in the face of hormonal suppression. 30:27 Now there’s something called calcetonin salamon which is marketed as miaelin. 30:34 It is a nasal spray. It is now discontinued. And foral is the new 30:39 synthetic polyeptide hormone of 32 amino acids identical to calcetonin of salamon 30:47 origin. It represents an interesting case study in how initial promise gives 30:52 way to safety concerns that regulate a therapy to historical footnote status. 30:58 Calcetonin is naturally occurring hormone in humans. It’s secreted by the paraphalicular sea cells in the thyroid 31:04 gland. Its primary physiological role is to lower blood calcium levels by 31:10 directly inhibiting osteoclast activity, reducing bone reabsorption, increasing 31:16 renal calcium secretion or excretion, and possibly reducing the intestinal 31:21 calcium absorption. So, salamon calcetonin is used therapeutically because it’s more potent and longer 31:27 acting than human calcetonin. The FDA initially approved calceton and salmon 31:34 for several indications post-menopausal osteoporosis in women more than five 31:39 years post-menopausal when alternative treatments are not sustainable. Padet’s 31:44 disease for bone and hypercalcemium as emergency treatments. The nasal spray formulation is particularly popular for 31:53 osteoporosis because it offered a non-injectable alternative to bisphosphinates. 31:58 However, in 2012, the European Medicine’s Agency, EMA, conducted a 32:05 comprehensive safety safety review after a poolled analysis of 21 clinical trials 32:10 involving over 10,000 patients showed a statistically significant increase in 32:15 malignancy risk in patients treated with calceton salamon compared to compared to 32:21 placebo. The overall malignancy rate was 4.1% in calcetonin treated patients 32:28 versus 2.9% in placebo patients. The types of cancer 32:34 varied with no single cancer type predominating, making it difficult to establish a clear mechanistic link. 32:41 However, the signal was concerning enough that the EMA restricted the use of calcetonin containing medicines. In 32:48 the United States, the FDA issued communications about malignancy signal and conducted its own review. While they 32:56 didn’t fully withdraw the drug, the cons consensus shifted dramatically. The nasal spray formulations miaelson was 33:03 voluntarily discontinued by the manufacturer and current clinical practice guidelines now consider 33:10 calcetonin salamon as a second line or lower option for osteoporosis. While 33:15 behind bisphosphinates, dennism mob, uh, terrapeptide, the analesic effect of 33:21 calcetonin in bone pain, particularly in acute vitibbral, uh, compression 33:26 fractions from osteoporosis or pageantss disease may still provide a role for short-term use in these selected 33:32 patients. The mechanism of this pain relief is unclear, but may involve 33:38 effects of endorphin systems and/or direct actions on pathways. The history serves as an important reminder in 33:45 peptide medicine. Initial approval and early clinical use does not guarantee 33:50 long-term safety effects. Post marketing surveillance and poolled analysis of the clinical trial data can reveal adverse 33:58 effects that weren’t apparent in initial studies. It also underscores why newer 34:04 agents with better safety profiles um have largely replaced calcetonin in 34:10 clinical practice. So this is really an important thing. Not one thing stays the same forever. We have to change as we 34:18 identify new and better products as we identify problems and concerns. I will 34:24 always tell my patients if you are uncertain of taking a new drug which we 34:30 all should be wait five years. Within five years we are going to find the 34:36 problems that they didn’t find in the clinical studies. Remember, a lot of these clinical studies are small, small 34:43 groups, short periods of time. It’s expensive to do these trials. So, if you 34:49 wait for five years, in the first two to three years, you will see the problem start to emerge. And what are you going 34:55 to look for? You’re going to look for the the news um commercials from lawyers 35:02 suing a drug. And they will tell you what the problem is. and then you can decide, is this something that I want to 35:09 use or not. Don’t jump on bandwagon and be the first one to do this, especially 35:14 if you’re sensitive. You know, give it time so you can see exactly what’s going on. So, I’m going to end our show on 35:22 this and we are going to pick up on part three of peptide therapy in our next 35:28 segment where we’re going to talk about the investigational peptides and some 35:34 exciting things that are happening with that. So, I want to thank you for joining me today on Let’s Talk Wellness 35:39 Now. It’s always a pleasure having a conversation with you guys and I hope this brings value to you with what we’re 35:45 talking about. If you have ideas for topics that you want me to discuss, 35:51 please message us, you can share your comments on Facebook, you can email us, 35:58 um you can get a hold of us however you would like to share that. I do look at the comments below in the episodes as 36:04 well. So you can place your comments there. And once again, one of the best things you can do for me is like, 36:11 subscribe, and share so that we can spread the messages of what we’re doing. 36:16 I do this at no cost. I don’t make any money out of this. I do this as an 36:21 educational purpose for everybody else. I love doing it, but it really helps us 36:28 on the algorithms if you would be just willing to like, subscribe, and share. 36:33 So, thank you for spending your time with me. I know time is important.The post Episode 257 – Peptides for Sexual Wellness & Hormonal Health: PT-141, Growth Hormones, Bone Health & More! first appeared on Let's Talk Wellness Now.

On this episode, we are joined by Sarah Doerrer, an occupational therapist and Certified Hand Therapist who is devoting most of her time these days to academia and research. She shares with us how she is connecting with clinicians in the community to collaborate on community-engaged research. We discuss the benefits to these collaborations, but also some of the barriers to clinical research and how to navigate those barriers. Sarah Doerrer, PhD, OTR/L, CHT, CLT graduated with her Masters in OT in 2001 from Misericordia University and her PhD in OT in 2019 from Nova Southeastern University. She is currently an assistant professor at George Washington University and worked in clinical practice for 22 years. She is a Certified Hand Therapist and Certified Lymphedema Therapist. Dr. Doerrer serves on the Research Division of the American Society of Hand Therapists and is the incoming Research Division chair and serves as the Education Chair for the Capital Hand Therapy Association. She has received two foundation grants for her dissertation research “The Impact of Shoulder Pathology on Individuals with Distal Radius Fracture” and received a grant from the American Hand Foundation for her clinical trial “Impact of Early ADL Participation on Functional Outcomes Post Distal Radius Fracture”. Dr. Doerrer has most recently been awarded the Hand in Hand Grant from AOTF-ASHT-AHTF and the Clinical Research Award from the American Hand Surgery Foundation for her work on post distal radius education. She is also a co-investigator on a Department of Education, Disability Innovation Fund grant. Dr. Doerrer has had multiple publications in the Journal of Hand Therapy and has published two book chapters. She is a reviewer for the Journal of Hand Therapy, Archives of Physical Medicine and Rehabilitation, and OT Journal of Research.The views and opinions expressed in the Hands in Motion podcast are those of the guests and do not necessarily reflect the official policy or position of ASHT. Appearance on the podcast does not imply endorsement of any products, services or viewpoints discussed"

This episode consists of audio from the first live streaming edition of our podcast, broadcast live on YouTube on February 26, 2026. The complete video of the live stream can be seen on our YouTube channel. The guests are Colby Thomas and Billy Simmons, who are historic interpreters at Old Cape Henry Lighthouse in Virginia – the first lighthouse commissioned by the federal government. Old Cape Henry Lighthouse, photo by Jeremy D’Entremo There are two lighthouses at Cape Henry, marking the south side of the entrance to the Chesapeake Bay. The older of the two lighthouses was built in 1792, and the sandstone tower stands 92 feet tall. The 1792 lighthouse eventually developed some cracks and a new, taller lighthouse was built in 1881. Since 1930, the Old Cape Henry Lighthouse has been owned and operated by Preservation Virginia. It was declared a National Historic Landmark in 1964, and in 2002 the American Society of Civil Engineers designated it lighthouse a National Historic Civil Engineering Landmark. Host Jeremy D’Entremont, co-host Sarah MacHugh, and guests Colby Thomas and Billy Simmons.

With Liemena Harold Adrian, Syarifah Ambami Rato Ebu General Academic Hospital, Surabaya - Indonesia and Shelley Zieroth, St. Boniface Hospital, Winnipeg - Canada.  In this episode, Liemena Harold Adrian and Shelley Zieroth discuss heart failure in post–myocardial infarction patients, covering how myocardial infarction leads to the development of heart failure despite advances in reperfusion and acute care. The conversation addresses the epidemiology and underlying pathophysiology, approaches to early prevention and screening, diagnostic tools, as well as key interventions in the acute and early post-MI phases that may alter heart failure trajectories. They outline management with guideline-directed medical therapy, review current studies on heart failure–modifying therapies (such as the DAPA-MI and EMPACT-MI trials), and address indications for advanced therapies in post-MI populations. The episode also highlights the importance of early diagnosis, prompt recognition, and key evidence gaps in the field. Recommended readings: Akhtar KH, Khan MS, Baron SJ, et al. The Spectrum of Post-Myocardial Infarction Care: From Acute Ischemia to Heart Failurehttps://doi.org/10.1016/j.pcad.2024.01.017. Prog Cardiovasc Dis. (2024); 82: 15-25. DOI: 10.1016/j.pcad.2024.01.017. Butler J, Hammonds K, Talha KM, et al. Incident Heart Failure and Recurrent Coronary Events Following Acute Myocardial Infarctionhttps://doi.org/10.1093/eurheartj/ehae885. Eur Heart J (2025); 46: 1540-50. DOI: 10.1093/eurheartj/ehae885. Butler J, Jones WS, Udell JA. Empagliflozin after Acute Myocardial Infarction. N Engl J Med (2024); 390: 1455-66. DOI: 10.1056/NEJMoa2314051. Fioretti F, Butler J, Udell JA, et al. Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI. ESC Heart Failure (2025); 12: 3940-3952. DOI: 10.1002/ehf2.15393. Hernandez AF, Udell JA, Jones WS. Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial. Circulation (2024); 149: 1627–1638. DOI: 10.1161/CIRCULATIONAHA.124.069217. Jenca D, Melenovsky V, Stehlik J, et al. Heart Failure after Myocardial Infarction: Incidence and Predictors. ESC Heart Failure (2021): 8: 222-237. DOI: 10.1002/ehf2.13144. Lala A, Beavers C, Blumer V, et al. The Continuum of Prevention and Heart Failure in Cardiovascular Medicine: A Joint Scientific Statement from the Heart Failure Society of America and The American Society for Preventive Cardiology. Journal of Cardiac Failure (2026); 32: 75-105. Petrie MC, Udell JA, Anker SD, et al. Empagliflozin in Acute Myocardial Infarction in Patients with and without Type 2 Diabetes: A Pre-specified Analysis of the EMPACT-MI Trial. Eur J of Heart Fail. (2025): 27: 577-588. DOI: 10.1002/ejhf.3548. Zieroth S, Rizi SS. Time Is of the Essence. JACC: Heart Failure (2023): 11(6): 713-714. DOI: 10.1016/j.jchf.2023.03.022 "This 2026 HFA Cardio Talk podcast series is supported by Bayer in the form of unrestricted financial support. The discussion has not been influenced in any way by its sponsors."

Dr. Paul Skinner discusses his career in viticulture and his time as a member of the Soil Science Society of America.   Contact us at podcast@sciencesocieties.org or on Twitter @FieldLabEarth if you have comments, questions, or suggestions for show topics, and if you want more content like this don't forget to subscribe. If you'd like to see old episodes or sign up for our newsletter, you can do so here: https://fieldlabearth.libsyn.com/.   If you would like to reach out to Paul, you can find him here: https://www.sequum.com/contact/ Resources Transcripts: https://www.rev.com/app/transcript/Njk5NzRjMTQ1ODkzNTI3MDhjMTA0YTg2ZXZHWFZsdlBldXFv/o/VEMwNDIzMzczNzAy  Sequum Wine: https://www.sequum.com/ Field, Lab, Earth is Copyrighted by the American Society of Agronomy, Crop Science Society of America, and Soil Science Society of America.

In this episode, we welcome Soledad O'Brien, Geeta Gandbhir, and Christalyn Hampton, the team behind the Oscar-nominated documentary short, The Devil Is Busy. Soledad serves as Executive Producer, with Geeta and Christalyn co-directing the film. The Devil Is Busy follows a day in the life of Tracii, the head of security at a women's healthcare clinic in Atlanta, who works tirelessly to protect the safety of the women who walk through its doors. In our conversation, the team shares on the origins of the project, the challenges of making it, and their creative workflows. They also reflect on the state of documentary film — and share advice for emerging filmmakers navigating today's landscape.“The Making Of” is presented by AJA:From cinema to proAV: gaining a competitive edge with streaming knowledgeThe worlds of cinema production and proAV are converging. Cinema-grade equipment is making its way into more stadiums, houses of worship, and concert venues. Because of this, professionals that understand the tools and disciplines powering both will stand out. Get ahead of the curve with the latest streaming insights and gear from AJA.Kodak Announces Honorees for the Eighth Annual Kodak Film AwardsAutumn Durald Arkapaw to Receive Lumiere Award; Kristen Stewart to Receive First Feature Award; Christopher Nolan to Present Inaugural Keighley AwardThe 8th Annual Kodak Film Awards will take place on Monday evening, March 2, 2026, at the American Society of Cinematographers (ASC) Clubhouse in Hollywood at an invitation-only event honoring Autumn Durald Arkapaw, Joachim Trier, Kristen Stewart, Patricia Keighley of IMAX, Salomon Ligthelm and the acclaimed television series Fallout. Read more hereNow with Massive 8TB Capacity—Thunderbolt 5 SpeedThe OWC Envoy Pro Ultra now comes in a new 8TB capacity, pairing enormous space with next‑generation Thunderbolt 5 performance. With real‑world speeds over 6000 MB/s and a rugged, bus‑powered design, it's perfect for 4K/8K workflows, on‑location shoots, and fast media offloads. High‑speed, high‑capacity, and ready for serious creative work. Browse hereFeature Your Brand:Showcase your products or services in “The Making Of” newsletter and reach 255K film & TV industry pros each week. To learn more, please email mvalinsky@me.comZEISS Aatma – Contemporary Full Frame Primes with a Soulful Legacy LookZEISS introduces the new Aatma, set of nine high-end full frame T1.5 cinema primes (18mm, 25mm, 35mm, 40mm, 50mm, 65mm, 85mm, 100mm, and 135mm) designed to marry the benefits of modern optical design with the nostalgic image characteristics that are popular today. Drawing inspiration from some of the most beloved ZEISS lenses of the 20th century, Aatma combines an emotion-driven look with the mechanical reliability, data integration, and workflow compatibility that's expected for current production. Read more hereA New Solution from Atomos:The Atomos Shogun AV-19 Rack-Mounted 4K HDR Monitor/Recorder/Switcher is your all-in-one solution for professional live production, combining a stunning 19” 4K HDR DCI-P3 display with quad-channel switching, real-time ISO recording of up to four camera feeds plus program out, and support for 10-bit Apple ProRes, ProRes RAW, and Avid DNx recording to CFexpress or USB-C media. Perfect for studios, video village, and broadcast environments, it delivers the monitoring accuracy and workflow efficiency your production demands. The Atomos Shogun AV-19 is available for pre-order now for $2,099.00. Learn more at Videoguys.com or call our production experts at 800-323-2325 today!Podcast Rewind:Feb. 2026 - Ep. 121. Get full access to The Making Of at themakingof.substack.com/subscribe

This week, we are so excited to share the first of our Career Development Series episodes, developed in partnership with The American Society of Hematology , The ASH Trainee Council, and Hematopoiesis! For years, our listeners have reached out to our show asking for guidance to help navigate their careers. We are so excited to be partnering with an amazing organization like ASH to help make this happen!This time, we welcome two amazing guests, Dr. Hetty Carraway, Director of the Leukemia Program and the Vice Chair of Strategy and Enterprise Development at the Taussig Cancer Institute at The Cleveland Clinic, and Dr. Alfred Lee, Chief of Classical Hematology at Yale School of Medicine, for our inaugural episode where we discuss the importance of mentorship and ask them all the questions most of us have always wondered but are too afraid to ask our mentors. A MUST listen for all trainees!** This episode is created in partnership with The American Society of Hematology (hematology.org), The ASH Trainee Council (https://www.hematology.org/education/trainees/fellows/trainee-council), and Hematopoeisis (https://www.hematology.org/education/trainees/fellows/hematopoiesis) ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube

Last time we talked about kidney xenotransplantation, we were joined by Towana Loony and Tim Andrews, who shared their personal experiences with receiving a xenotransplant. Today, two doctors who helped propel xenotransplantation forward, Dr. Vineeta Kumar and Dr. Leonardo Riella, are here to explain the science and what comes next. This episode is supported by eGenesis and United Therapeutics In this episode we heard from:  Vineeta Kumar is the lead nephrologist for UAB's Living Kidney Donor and Incompatible Kidney Transplant programs. She is an expert in kidney transplantation, living kidney donation, incompatible kidney transplant, kidney paired donation and cardiovascular outcomes after kidney transplantation. Kumar also engages in research in the prevention, treatment and prognosis of antibody mediated rejection. She has been named a "Top Doctor" by U.S. News & World Report each year since 2012. She has been lead facilitator of the UAB Schwartz Rounds since 2009, a program that brings together nurses, physicians, social workers, and other providers to discuss delivery of compassionate care. She was awarded the Brewer-Heslin Endowed Award for Professionalism in Medicine for the highly skilled and compassionate medical care she provides to her patients. Kumar was recently named "Best Educator" by the 2018, 2019 and 2020 UAB Medical School classes. She has previously served on the Education Committee for the American Society of Transplantation. Leonardo V. Riella, M.D., Ph.D. is the Harold and Ellen Danser Endowed Chair in Transplant Surgery at Harvard Medical School and the Medical Director of Kidney Transplantation at Massachusetts General Hospital. His research focuses on mechanisms of immune regulation and the development of novel therapies to promote transplant tolerance. In addressing kidney disease recurrence post-transplantation, he founded and leads the TANGO Consortium, the largest global effort dedicated to studying glomerular disease recurrence. In March 2024, Dr. Riella led the world's first successful kidney xenotransplant from a gene-edited pig into a living human. He now leads the first FDA-approved pilot study in kidney xenotransplantation and is conducting high-dimensional immune profiling studies to characterize the human xeno-immune response and guide immunosuppressive strategies. Find out more about Dr. Riella's research here.     Additional Resources Xenotransplantation Information   Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.

Join us for an inspiring and deeply informative episode featuring Dr. Christine N. Booth, the 2025–2026 President of the American Society of Cytopathology (ASC). Dr. Booth brings more than two decades of experience in cytopathology, breast pathology, and medical leadership, and currently serves as the Director of Regional Cytology at the Cleveland Clinic.  Whether you're a cytologist, pathologist, trainee, or simply fascinated by the science and stories behind cellular diagnostics, this episode offers a rare, engaging look at her leadership, why being active at the ASC is important, and the heart of cytopathology. Christine Booth, MD Cleveland Clinic ASC President   Terri Jones, MD University of Pittsburgh Medical Center (UPMC) Member, The ASC Bulletin & CytoPathPod Editorial Board

When neuroscientists scanned the brains of people going along with a group, they expected to find lying. What they found instead was something far stranger. The group wasn't changing people's answers. It was changing what they actually saw. We'll get to that study in a minute. But first, I want you to remember the last time you were in a meeting, and you knew something was wrong. The numbers didn't add up. The risk was being underestimated. And someone needed to say it. Then the most senior person in the room spoke first: "I think this is exactly what we need." Heads nodded. Finance agreed. Marketing agreed. The consultant agreed. And by the time it was your turn, you heard yourself saying, "I have some minor concerns, but overall I think it's solid." You're not alone. Research shows that roughly half of employees stay silent at work rather than voice a concern. And among those who stayed quiet, 40% estimated they wasted 2 weeks or more replaying what they didn't say. Two weeks. Mentally rehearsing the point they should have made in a meeting that's already over. That silence isn't a character flaw. It's your neurology working against you. And today I'm going to show you exactly why it happens and how to stop it.  It starts with what was happening inside your head during that meeting you just remembered. Why Your Brain Surrenders to the Group Most people know about the Asch conformity experiments from the 1950s. People were asked to match line lengths, and seventy-five percent went along with answers that were obviously wrong. That result gets cited everywhere. But the more important study came fifty years later, and it revealed something the Asch experiment never could. In 2005, neuroscientist Gregory Berns at Emory University put people inside an MRI machine and ran a similar conformity task, this time with three-dimensional shape rotation. Like Asch, he planted actors who gave wrong answers. But unlike Asch, he could watch what was happening inside people's brains while the conformity was occurring. Berns expected the MRI to show activity in the prefrontal cortex, the brain's decision-making center, when people went along with wrong answers. That would mean they were knowingly lying to fit in. Just a social calculation. That's not what the scans showed. People who conformed showed no increased activity in decision-making regions. Instead, the activity showed up in the parts of the brain that handle visual and spatial perception, the occipital and parietal areas. The group wasn't changing people's answers. It was changing what they actually saw. Their brains were rewriting their experience to match the room. And the people who resisted the group? Their scans told a different story. Heightened activity in the amygdala, the brain's threat detection center. The same circuitry that fires when you encounter physical danger lit up when someone disagreed with the group. Berns put it plainly. The fear of social isolation activates the same neural machinery as the fear of genuine threats to survival. When you caved in that meeting, your neurology wasn't malfunctioning. It was doing exactly what it was designed to do. Keep you safe inside the tribe. This is why what I call mindjacking works so well. Algorithms manufacture social proof by showing you what's trending, what your friends liked, and what similar people chose. Your wiring responds the same way it does at the conference table. You're fighting your own threat-detection system every time you try to hold an independent position within a group. You can't turn off the wiring. But you can learn to catch it in the act. And that starts with one critical distinction. The First Skill: Separating Updating from Caving Sometimes the people around you know something you don't. Changing your mind in a group isn't always a surrender. Sometimes it's the smartest move in the room. The real skill is knowing which one just happened. You can test this in real time. When you feel your position shifting in a group, ask yourself three questions. First: Did someone introduce information I didn't have before? If the CFO reveals a data point that genuinely changes the calculus, updating your view isn't a weakness. It's intelligence. That's new evidence. Second: Can I articulate why I changed my mind, in specific terms? If you can say, "I shifted because of the margin data in Q3 that I hadn't seen," that's a real update. If you can only say, "I don't know, everyone seemed to think it was fine," that's capitulation. Third: Would I have reached this same conclusion alone, with the same information? This is the killer question. If the answer is no, and you only arrived at this position because others were already there, you haven't updated. You've surrendered. Getting this wrong is costly. And not just the one time. When you capitulate and call it updating, you train yourself to stop trusting your own analysis. Do it enough times, and you won't even bother preparing, because you already know you're going to defer. That's how capable people slowly become passengers in rooms where they should be driving. Capture those three questions somewhere you'll see them. They're your real-time check on whether you're being open-minded or spineless. Those questions work when you're already in the meeting and the pressure is live. But what if you could protect your thinking before the pressure even starts? The Pre-Meeting Lock-In The most important thing you can do to protect your independent thinking doesn't happen during the meeting. It happens before. I call it the Pre-Meeting Lock-In, and it takes less than two minutes. Before any meeting where a decision will be made, write down three things:  Your position  Two or three key reasons supporting it What would it take to change your mind Put it on paper. Put it in a note on your phone. Just get it out of your head and into a form you can reference. Why does this work? Because once the discussion starts, your mind is going to quietly edit your memories of what you believed. You'll start thinking, "Well, I wasn't really sure about that point anyway." Your pre-meeting notes are an anchor against that self-deception. They're a record of what you actually thought before the social pressure arrived. You want to see what happens when someone has the analysis but doesn't lock it in?  The night before the Challenger launch in January 1986, engineer Roger Boisjoly and his team at Morton Thiokol had the data. They knew the O-ring seals were dangerous in cold weather. They'd written memos. They'd run the numbers. They recommended against launching. But when NASA pushed back hard on the teleconference, Thiokol management called an off-line caucus and excluded the engineers from the room. When the call resumed, management reversed the recommendation. Boisjoly had the analysis. His managers had heard it. But under pressure from their biggest customer, the conclusion got edited in real time. Boisjoly later described it as an unethical forum driven by what he called "intense customer intimidation." He fought like hell, but the room won. That's the most extreme version of the problem. Life and death. But the mechanics are the same in every conference room. The analysis exists. The pressure arrives. And without something anchoring you to what you actually concluded, the room rewrites the story. There's a bonus effect to the Lock-In, too. When you've documented what it would take to change your mind, you've given yourself permission to be genuinely open. You're not being stubborn for the sake of it. You're saying, "Show me evidence that meets this threshold, and I'll update." That's intellectual honesty with a backbone. But you can know exactly what you think and still fail if you can't get anyone else to hear it. How to Dissent and Actually Be Heard Most dissent fails not because it's wrong, but because it's delivered badly.  Blurting out "I think this is a mistake" when the group is already aligned feels like an attack. People get defensive. Your point gets ignored, not because it lacked merit, but because your delivery threatened the group's cohesion. You triggered the same threat response in them that you've been learning to manage in yourself. Charlan Nemeth, a psychologist at UC Berkeley, has studied dissent for decades. You'd expect her research to show that dissent helps groups when the dissenter is right. When someone spots a flaw that everyone else missed. That makes intuitive sense. But that's not what she found. Nemeth discovered that when someone voices a genuine minority opinion, the entire group thinks more carefully. They consider more information, examine more alternatives, and reach better conclusions. And the group benefits even when the dissenter turns out to be wrong. Even when you're wrong, the act of dissenting makes the group smarter. Your disagreement forces everyone out of autopilot. Decades of research by Moscovici supports this. Minority voices don't just influence people in the moment. They shift perception afterward, in private, long after the meeting ends. That's the good news. The catch is in how the dissent happens. Nemeth tested what happens when dissent is assigned rather than authentic, when someone plays devil's advocate because they were told to. It doesn't produce the same effect. Groups can tell when disagreement is performative. The cognitive benefits only show up when the dissent is authentic. When someone actually believes what they're saying. That means the goal isn't just to voice disagreement. It's to voice it in a way that people can actually receive. And the hardest version of this isn't when you have a minor concern about an otherwise good plan. It's when the whole direction is wrong, and finding something to praise would be dishonest. In those moments, the move is to separate the people from the position. "I respect the work that went into this, and I know this isn't what anyone wants to hear, but I think we're solving the wrong problem." You're honoring the effort while challenging the direction. You're not attacking the tribe. You're trying to save it from a bad bet. When the stakes are lower, and you do see genuine merit, you can lead with that. "The market timing argument is strong, and I want to make sure we've stress-tested one thing before we commit." Same principle. You're working with their wiring instead of against it. Either way, your dissent has value beyond being right. Remember that. It's worth holding onto when your amygdala is screaming at you to stay quiet. Everything so far has assumed you're in a room with other people. Your amygdala can't tell the difference between a conference table and a phone screen. The Rooms You Can't See You're not just in meetings. You're in invisible rooms all day long. And most of the time, you don't even know you've walked into one. Every time you scroll past a post with ten thousand likes and think, "I guess that's the right take." Every time you read three articles with the same conclusion and stop questioning it. Every time an algorithm shows you what similar people chose, and you choose it too. Those are rooms full of nodding heads. And your amygdala responds to them the same way it responds to the conference table. Think about the last time you researched a major purchase. You probably started with some idea of what you wanted. Then you read reviews. Then you checked what was trending. Then you asked friends. By the time you decided, how much of that decision was yours? How much of it was the room? Or think about how you form opinions on topics you haven't studied deeply. You read a few articles. They mostly agree. You adopt the consensus. That feels like research. But Berns' scans tell us what's actually happening. Your brain isn't independently weighing the evidence. It's detecting a consensus and rewriting your perception to match. The same process that happens at the conference table is happening every time you open your phone. Mindjacking doesn't need to override your thinking. It just needs to make sure you never finish thinking for yourself before the crowd's answer arrives. And once it arrives, your neurology does the rest. The group doesn't just influence your answer; it shapes it. It rewrites your perception. The Lock-In works for these invisible rooms, too. Before you research a major purchase, write down what you actually want and what you're willing to pay. Before you dive into reviews and opinions, commit your criteria to paper. Before you ask friends what they think about a decision you've already analyzed, record your conclusion. Give yourself the same protection from algorithmic conformity that you'd want before walking into a boardroom. The skill isn't being contrarian. It's being first. First, to your own conclusion, before the room, any room, gets a vote. This is your challenge for the week. Think of one meeting you have coming up where a decision will be made. Before you walk in, open your notes app and type three lines. Line one: what you think. Line two: why. Line three: what would change your mind. That's it. Then sit in that meeting and watch what happens to your thinking when the room pushes back. I think you'll surprise yourself. What if the person you can't resist isn't your boss, your colleagues, or the algorithm? What if it's you? What happens when the decision you need to make threatens something deeper, when being wrong would mean something unbearable about who you are? That's where we're headed next. Closing If this episode gave you something useful, hit that subscribe button. I'm building a complete thinking toolkit here in the Thinking 101 series. If you got value today, share it with someone who could use it, especially anyone heading into a big meeting this week. Drop a comment and tell me: what's the hardest group you've ever had to disagree with? I read every comment and reply. Thanks for watching, and I'll see you in the next episode. Endnotes/References "roughly half of employees stay silent at work rather than voice a concern" / "forty percent estimated they wasted two weeks or more": VitalSmarts, Costly Conversations: Why The Way Employees Communicate Will Make or Break Your Bottom Line (Provo, UT: VitalSmarts, December 2016). In a study of 1,025 employees, 70 percent reported instances where they or others failed to speak up effectively when a peer did not pull their weight. Half wasted seven days or more avoiding crucial conversations. Forty percent estimated they wasted two weeks or more ruminating about the problem. A 2021 follow-up study by Crucial Learning (formerly VitalSmarts) of 1,100 people found the rumination figure had risen to 43 percent. The script's "roughly half" is drawn from the VitalSmarts finding that the majority of the workforce reported conversation failures, with half losing seven or more days to avoidance behaviors. Primary source: https://www.vitalsmarts.com/press/2016/12/costly-conversations-why-the-way-employees-communicate-will-make-or-break-your-bottom-line/. Follow-up study: https://cruciallearning.com/press/costly-conversations-how-lack-of-communication-is-costing-organizations-thousands-in-revenue/ "the Asch conformity experiments from the 1950s": Solomon E. Asch, "Effects of Group Pressure upon the Modification and Distortion of Judgments," in Groups, Leadership and Men, ed. Harold Guetzkow (Pittsburgh: Carnegie Press, 1951), 177–190. The expanded report was published as Solomon E. Asch, "Studies of Independence and Conformity: I. A Minority of One Against a Unanimous Majority," Psychological Monographs: General and Applied 70, no. 9 (1956): 1–70. Asch conducted the line-judgment experiments at Swarthmore College. Participants judged which of three comparison lines matched a standard line, with confederates unanimously giving incorrect answers on critical trials. Across conditions, approximately 75 percent of participants conformed at least once, and the mean conformity rate was approximately one-third of critical trials. Group sizes varied across experiments, typically with 6–8 confederates and one real participant. https://psycnet.apa.org/record/1952-00803-001 "neuroscientist Gregory Berns at Emory University put people inside an MRI machine": Gregory S. Berns, Jonathan Chappelow, Caroline F. Zink, Giuseppe Pagnoni, Megan E. Martin-Skurski, and Jim Richards, "Neurobiological Correlates of Social Conformity and Independence During Mental Rotation," Biological Psychiatry 58, no. 3 (August 1, 2005): 245–253. doi:10.1016/j.biopsych.2005.04.012. The study used functional magnetic resonance imaging with a mental rotation task. Participants (n=32, ages 19–41) judged whether three-dimensional shapes were rotated versions of each other while four confederates provided answers. Conformity was associated with functional changes in the occipital-parietal network (visual and spatial perception regions), not the prefrontal cortex. Independence was associated with heightened activity in the right amygdala and right caudate nucleus, regions linked to emotional salience and threat detection. https://pubmed.ncbi.nlm.nih.gov/15978553/ "The group wasn't changing people's answers. It was changing what they actually saw": Berns et al., "Neurobiological Correlates of Social Conformity," 245–253. The researchers isolated the specifically social element of conformity by comparing brain activation when wrong answers came from a group of people versus when they came from computers. Conformity to group-sourced wrong answers produced greater activation bilaterally in visual cortex and right intraparietal sulcus, overlapping the baseline mental rotation network. Berns interpreted this as evidence that social conformity operates at a perceptual level rather than merely at a decision-making level. Full text PDF: https://pdodds.w3.uvm.edu/files/papers/others/2005/berns2005.pdf "Heightened activity in the amygdala": Berns et al., "Neurobiological Correlates of Social Conformity," 245–253. Participants who gave independent (correct) answers when the group was wrong showed significantly increased activation in the right amygdala and right caudate nucleus. The amygdala is associated with processing emotionally salient stimuli and threats. Berns described these findings as "consistent with the assumptions of social norm theory about the behavioral saliency of standing alone." The script's characterization that "the fear of social isolation activates the same neural machinery as the fear of genuine threats to survival" is an accessible paraphrase of this finding, consistent with the broader social pain literature (e.g., Eisenberger, Lieberman, & Williams, 2003), though Berns' paper does not use that exact language. https://pubmed.ncbi.nlm.nih.gov/15978553/ "engineer Roger Boisjoly and his team at Morton Thiokol had the data": Roger M. Boisjoly, "Ethical Decisions — Morton Thiokol and the Space Shuttle Challenger Disaster" (paper presented at the American Society of Mechanical Engineers Annual Meeting, December 13–18, 1987). First presented as a talk at MIT in January 1987. Boisjoly, a specialist in O-ring seals and rocket joints at Morton Thiokol, documented how engineers recommended against the January 28, 1986 launch based on concerns about O-ring performance in cold temperatures. During the pre-launch teleconference, Thiokol management called an off-line caucus, excluded the engineers, and reversed the no-launch recommendation under pressure from NASA. Boisjoly described the forum as constituting "the unethical decision-making forum" driven by customer pressure. He was awarded the Prize for Scientific Freedom and Responsibility by the American Association for the Advancement of Science. The Online Ethics Center at the National Academy of Engineering hosts Boisjoly's full account: https://onlineethics.org/cases/ethical-decisions-morton-thiokol-and-space-shuttle-challenger-disaster-introduction. See also Russell P. Boisjoly, Ellen Foster Curtis, and Eugene Mellican, "Roger Boisjoly and the Challenger Disaster: The Ethical Dimensions," Journal of Business Ethics 8, no. 4 (April 1989): 217–230. doi:10.1007/BF00383335. https://link.springer.com/article/10.1007/BF00383335 "Nemeth discovered that when someone voices a genuine minority opinion, the entire group thinks more carefully": Charlan J. Nemeth, In Defense of Troublemakers: The Power of Dissent in Life and Business (New York: Basic Books, 2018). Nemeth's research program at UC Berkeley, spanning four decades, demonstrated that exposure to minority dissent stimulates divergent thinking, broader information search, consideration of more alternatives, and higher-quality group decisions. The finding that dissent improves group performance even when the dissenter turns out to be wrong is documented across multiple studies. See also Charlan J. Nemeth, "Minority Influence Theory," IRLE Working Paper No. 218-10 (Berkeley: Institute for Research on Labor and Employment, May 2010). https://escholarship.org/uc/item/1pz676t7 "Decades of research by Moscovici": Serge Moscovici, Elisabeth Lage, and Martine Naffrechoux, "Influence of a Consistent Minority on the Responses of a Majority in a Color Perception Task," Sociometry 32, no. 4 (December 1969): 365–380. In the original experiment, participants viewed blue slides while two confederates consistently called them green. The consistent minority condition produced a shift in approximately 8 percent of majority judgments toward the minority position, and roughly one-third of participants conformed at least once. In the inconsistent minority condition, the effect was negligible (approximately 1.25 percent). The script's claim that "minority voices don't just influence people in the moment — they shift perception afterward, in private" draws on Moscovici's subsequent conversion theory and research on the delayed and private effects of minority influence, including afterimage studies showing genuine perceptual shifts. https://www.jstor.org/stable/2786541 "Nemeth tested what happens when dissent is assigned rather than authentic": Charlan J. Nemeth, Joanie B. Connell, John D. Rogers, and Keith S. Brown, "Improving Decision Making by Means of Dissent," Journal of Applied Social Psychology 31, no. 1 (2001): 48–58. doi:10.1111/j.1559-1816.2001.tb02481.x. Groups deliberated a personal injury case under three conditions: authentic dissent (a genuine minority viewpoint), assigned devil's advocate (a member told to argue the opposing side), and no dissent. Authentic dissent was superior in stimulating consideration of opposing positions, original thought, and direct attitude change. The devil's advocate condition did not produce the same cognitive benefits, suggesting that groups detect and discount performative disagreement. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1559-1816.2001.tb02481.x. See also Charlan Nemeth, Keith Brown, and John Rogers, "Devil's Advocate versus Authentic Dissent: Stimulating Quantity and Quality," European Journal of Social Psychology 31, no. 6 (2001): 707–720. doi:10.1002/ejsp.58.

How do you respond when someone says or does something disrespectful to you? Admin expert Sandy Geroux shares some advice and more ways to command the respect you deserve. Recorded at APC 2025 and produced by the American Society of Administrative Professionals - ASAP. Learn more and submit a listener question at asaporg.com/podcast.

In this episode, we welcome Adolpho Veloso, ABC, AIP. Adolpho is the Oscar-nominated cinematographer of Train Dreams, which has been nominated for 4 Academy Awards. In our chat, he shares his origin story, how he learned his craft, and all about the making of this period drama. Adolpho also provides insights into both the creative and technical aspects of his cinematography, as well as recommendations for younger filmmakers today. “The Making Of” is presented by AJA:From cinema to proAV: gaining a competitive edge with streaming knowledgeThe worlds of cinema production and proAV are converging. Cinema-grade equipment is making its way into more stadiums, houses of worship, and concert venues. Because of this, professionals that understand the tools and disciplines powering both will stand out. Get ahead of the curve with the latest streaming insights and gear from AJA.Kodak Announces Honorees for the Eighth Annual Kodak Film AwardsAutumn Durald Arkapaw to Receive Lumiere Award; Kristen Stewart to Receive First Feature Award; Christopher Nolan to Present Inaugural Keighley AwardThe 8th Annual Kodak Film Awards will take place on Monday evening, March 2, 2026, at the American Society of Cinematographers (ASC) Clubhouse in Hollywood at an invitation-only event honoring Autumn Durald Arkapaw, Joachim Trier, Kristen Stewart, Patricia Keighley of IMAX, Salomon Ligthelm and the acclaimed television series Fallout.Kristen Stewart will be honored with the Debut Feature Award for her directorial debut, The Chronology of Water. The award recognizes first-time filmmakers who bring a distinctive voice and vision to their inaugural feature. Past recipients of the First Feature Award include Céline Song, Michael Morris, and Melina Matsoukas.Read more hereNow with Massive 8TB Capacity—Thunderbolt 5 SpeedThe OWC Envoy Pro Ultra now comes in a new 8TB capacity, pairing enormous space with next‑generation Thunderbolt 5 performance. With real‑world speeds over 6000 MB/s and a rugged, bus‑powered design, it's perfect for 4K/8K workflows, on‑location shoots, and fast media offloads. High‑speed, high‑capacity, and ready for serious creative work.Browse hereZEISS Aatma – Contemporary Full Frame Primes with a Soulful Legacy LookZEISS introduces the new Aatma, set of nine high-end full frame T1.5 cinema primes (18mm, 25mm, 35mm, 40mm, 50mm, 65mm, 85mm, 100mm, and 135mm) designed to marry the benefits of modern optical design with the nostalgic image characteristics that are popular today. Drawing inspiration from some of the most beloved ZEISS lenses of the 20th century, Aatma combines an emotion-driven look with the mechanical reliability, data integration, and workflow compatibility that's expected for current production. Read more hereA New Solution from Atomos:The Atomos Shogun AV-19 Rack-Mounted 4K HDR Monitor/Recorder/Switcher is your all-in-one solution for professional live production, combining a stunning 19” 4K HDR DCI-P3 display with quad-channel switching, real-time ISO recording of up to four camera feeds plus program out, and support for 10-bit Apple ProRes, ProRes RAW, and Avid DNx recording to CFexpress or USB-C media. Perfect for studios, video village, and broadcast environments, it delivers the monitoring accuracy and workflow efficiency your production demands. The Atomos Shogun AV-19 is available for pre-order now for $2,099.00. Learn more at Videoguys.com or call our production experts at 800-323-2325 today!Podcast Rewind:Feb. 2026 - Ep. 120.Feature Your Brand: Showcase your products or services in “The Making Of” newsletter and reach 255K film & TV industry pros each week. To learn more, please email mvalinsky@me.com Get full access to The Making Of at themakingof.substack.com/subscribe

Josh Rogin reveals the Bingo Club, a secret group tracking Chinese influence in American society, and discusses allegations regarding elite corruption and the CCP's United Front operations. 3

Every single week in my clinic, I see smart, motivated people stuck in their weight loss journey not because they're doing something wrong, but because they believe something wrong. The myths surrounding weight loss are so deeply embedded in our culture that even some physicians still repeat them. And the cost? Shame, delayed treatment, and people giving up on themselves unnecessarily. I've spent over a decade watching these myths do real damage and I'm done staying quiet about it. In this episode, I'm breaking down the top 5 weight loss myths I wish my patients would stop believing and replacing them with what the science actually says. If you've ever said "I just need more willpower" this episode is for you. Listen now!   Episode Highlights: Why "calories in, calories out" is an oversimplification of a complex metabolic system How metabolic adaptation explains why what worked before stops working Why obesity is a chronic, relapsing disease  The truth about weight loss medications and why using them is NOT cheating Why the scale is just data, not a report card, and what metabolic progress really looks like Why stopping everything after weight loss leads to weight regain, and what to do instead   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Jeremi and Zachary speak with historian Heather Ann Thompson about her book "Fear and Fury," using the 1984 Bernie Goetz subway case to explore how Reagan-era, rising inequality, and a newly powerful conservative media reshaped public attitudes about crime, race, and self-defense. They connect the episode to figures like Rupert Murdoch, Donald Trump, and Rudy Giuliani, and to the often-overlooked lives of the four teenagers at the center of the story. Dr. Heather Ann Thompson is a historian at the University of Michigan, and is the Pulitzer Prize and Bancroft Prize-winning author of Blood in the Water: The Attica Prison Uprising of 1971 and Its Legacy (Pantheon Books, 2016). Her latest book is Fear and Fury: The Reagan 80s, the Bernie Goetz Shootings, and the Rebirth of White Rage (Pantheon, 2026).

Send a textAbout Dr. Rishi P. Singh MD,Dr. Rishi P. Singh MD is a staff surgeon, vice president, and chief medical officer at theCleveland Clinic Martin Health and Professor of Ophthalmology at the Lerner College of Medicine in Cleveland Ohio. He received his bachelors and medical degrees from Boston University and completed his residency at the Massachusetts Eye and Infirmary Harvard Combined Program in Boston, Massachusetts. Dr. Singh then completed a medical and surgical fellowship at the Cole Eye Institute in Cleveland, Ohio.He specializes in the treatment of medical and surgical retinal disease such as diabeticretinopathy, retinal detachment, and age-related macular degeneration. Dr. Singh hasauthored more than 250 peer reviewed publications, books, and book chapters and serves as the principal investigator of numerous national clinical trials advancing the treatment of retinal disease. Dr. Singh is the former president on the Retina World Congress and is on the board of the American Society of Retina Specialists.Dr. Singh has been honored with several research recognitions such as the Alpha Omega Alpha Research Award and American Society of Retina Specialists Senior Honor Award.

Millions of Americans are turning to GLP-1 weight loss medications like Ozempic and Wegovy. But here's the question few are asking: What happens when you stop? Research shows that many people regain a significant portion of the weight within a year of discontinuing GLP-1 medications. In some studies, participants regained as much as two-thirds of the weight they lost. On this episode of The Exam Room, Chuck Carroll sits down with world-renowned obesity researcher James Hill, PhD to unpack the real story behind long-term weight management after GLP-1 medications. Dr. Hill is a pioneering scientist and former president of The Obesity Society and The American Society for Nutrition. Along with Dr. Holly Wyatt, he co-authored the new book Losing the Weight Loss Meds: A 10-Week Playbook for Stopping GLP-1 Medications Without Regaining the Weight. In this conversation, you'll learn: • Are GLP-1 medications meant to be long-term? • What happens inside the body when you stop taking them • Why so many people regain weight after discontinuing • The 10-week transition strategy for maintaining weight loss • The three types of weight regain—and how to avoid each • How to quiet food noise and cravings naturally • Daily habits that can replace the work of GLP-1 medications Chuck also shares his personal perspective on long-term weight loss success, including: • What he's learned after weight loss surgery • The lifestyle shifts that made his results sustainable • And what he wishes he knew before surgery that he knows now If you're considering GLP-1 medications, currently using them, or thinking about stopping, this episode could change how you approach weight maintenance forever.

Independent journalist Benjamin Ryan was the only reporter who sat through all three weeks of the first-ever detransition malpractice trial. He and Bridget discuss the chilling testimony of a mother who was browbeaten until she consented to her daughter's mastectomy, a 15-year-old's 11-month sprint from questioning her gender to surgery, and why the psychologist was an “enabler” instead of an measured professional. They cover the judge who tried to scare Ryan off reporting, why detransitioners get ghosted by the same medical system that celebrated them when they were trans, the suicide prevention data that doesn't actually support youth transition, how “gender affirmation” became coercive, and American Society of Plastic Surgeons suddenly changing their stance on surgery for minors. They also talk about the Epstein files as a full-time addiction, GLP-1s dominating suburban birthday party conversations, the collapse of traditional newsrooms versus the rise of Substack, and why conservative outlets are doing better science journalism than liberal media. Check out Bejamin's Substack - https://benryan.substack.com/ ---------------------------------------------------------------------- Sponsor Links: - Quest offers 100+ lab tests to empower you to have more control over your health journey. Choose from a variety of test types that best suit your needs, use code WALKINS25 to get 25% off - https://www.questhealth.com - Transform your fitness with science based training. Start free with Caliber - https://caliberstrong.com/phetasy --------------------------------------------------------------------- Walk-Ins Welcome with Bridget Phetasy - Podcast Bridget Phetasy admires grit and authenticity. On Walk-Ins Welcome, she talks about the beautiful failures and frightening successes of her own life and the lives of her guests. She doesn't conduct interviews—she has conversations. Conversations with real people about the real struggle and will remind you that we can laugh in pain and cry in joy but there's no greater mistake than hiding from it all. By embracing it all, and celebrating it with the stories she'll bring listeners, she believes that our lowest moments can be the building blocks for our eventual fulfillment. ---------------------------------------------------------------------- PHETASY IS a movement disguised as a company. We just want to make you laugh while the world burns. https://www.phetasy.com/ Buy PHETASY MERCH here: https://www.bridgetphetasy.com/ For more content, including the unedited version of Dumpster Fire, BTS content, writing, photos, livestreams and a kick-ass community, subscribe at https://phetasy.com/ Twitter - https://twitter.com/BridgetPhetasy Instagram - https://www.instagram.com/bridgetphetasy/ Podcast - Walk-Ins Welcome with Bridget Phetasy https://itunes.apple.com/us/podcast/walk-ins-welcome/id1437447846 https://open.spotify.com/show/7jbRU0qOjbxZJf9d49AHEh https://play.google.com/music/listen?u=0#/ps/I3gqggwe23u6mnsdgqynu447wvaSupport the show

This followed a jury in Westchester County awarding a woman $2 million in damages for her double mastectomy. Constitutional expert, lawyer, author, pastor, and founder of Liberty Counsel Mat Staver discusses the important topics of the day with co-hosts and guests that impact life, liberty, and family. To stay informed and get involved, visit LC.org.

Amanda Troxler has been practicing family formation law since 2013. She represents hundreds of Intended Parents, Donors, and Surrogates a year. Additionally, Amanda has personal experience in third party assisted reproduction, having been an egg donor. In today's show we are going to explain what family formation law is. As a fertility patient, it's important that you understand some of the basic legal pieces that you might want to have in place for your journey, whether that be for IVF, or if you're going to be using donor eggs, donor sperm, or using a gestational carrier. I very much love Amanda's thoughtful and caring approach to making family formation law approachable. As she says, "healthy families are formed through honest communication and centering the needs of the future child." Amanda received her J.D. from UCLA law on a Dean's Merit Scholarship in 2012. She received her Bachelor of Arts degree from Northwestern University in 2008. Amanda is a member of the Academy of California Adoption-ART Lawyers ("ACAL"), Society for Ethics in Egg Donation and Surrogacy ("SEEDS"), and American Society of Reproductive Medicine ("ASRM"). Thank you for joining me, Amanda! Read the full show notes and transcript at Dr. Aimee's website. You can find Amanda's site at troxlaw.com Would you like to ask Dr. Aimee your personal IVF questions? Click here to join Dr. Aimee for The IVF Class. The next live class call is on Monday, March 9th, 2026 at 4pm PST, where Dr. Aimee will explain IVF and there will be time to ask her your questions live on Zoom.   Dr. Aimee Eyvazzadeh is one of America's most well known fertility doctors. Her success rate at baby-making is what gives future parents hope when all hope is lost. She pioneered the TUSHY Method and BALLS Method to decrease your time to pregnancy. Learn more about the TUSHY Method and find a wealth of fertility resources at www.draimee.org  where you can schedule a consultation. More ways to connect with Dr. Aimee: Subscribe to my YouTube channel for more fertility tips! Subscribe to the newsletter to get updatesFollow on Instagram

The American Society of Plastic Surgeons has released an updated statement recommending against gender surgeries for anyone under the age of 18. While the American Medical Association has issued a similar stance, other organizations—including the American Academy of Pediatrics—argue that healthcare decisions should remain between families and doctors, and that surgical options should stay on the table for minors. Earlier this week, plastic surgeon and star of Netflix's Skin Decision: Before and After, Dr. Sheila Nazarian, joined FOX News Rundown host Dave Anthony to explain why many in her field believe minors should not "go under the knife" for transition procedures. Dr. Nazarian raised alarms over the lack of long-term data regarding the effectiveness of these treatments, emphasizing her belief that evidence-based medicine must be the sole guide for treating gender dysphoria in children. She also discussed the professional risks of speaking out, noting that many in the medical community fear political backlash for questioning current standards of care. We often have to cut our interviews short during the week, but we thought you might like to hear this conversation in its entirety. Today on a Fox News Rundown Extra, we share our full interview with plastic surgeon Dr. Sheila Nazarian. Learn more about your ad choices. Visit podcastchoices.com/adchoices

The medical community is finally realizing that transgender surgeries are harming America’s children. Recently, both the American Society of Plastic Surgeons and the American Medical Association released statements recommending gender-affirming surgeries be delayed until adulthood, but what does this mean for the issue as a whole? Is change happening? Host Casey Harper is joined by American Parents Coalition’s Alleigh Marre, and The Washington Stand’s Joshua Arnold to discuss the new research and mentality shift we are seeing in the medical world.

Stay informed on current events, visit www.NaturalNews.com - Glyphosate in Bread: Introduction and Initial Findings (0:10) - Detailed Analysis of Glyphosate Levels in Bread (12:13) - Health Ranger Lab Tour and Instrument Demonstration (12:29) - Epstein Files and Conspiracy Theories (27:59) - Cannibalism and Child Exploitation in Epstein Files (32:51) - Impact of AI on the Workforce (39:46) - Economic and Social Implications of AI Automation (1:07:24) - Government Response to AI-Driven Job Displacement (1:07:49) - Predictions for the Future of AI and Workforce Automation (1:08:13) - Humanity's Last Exam and Mass Replacement (1:15:10) - Government's Role in Population Control (1:22:58) - Preparedness and Survival Strategies (1:25:30) - Iran's Bunker Buster Bomb and Reverse Engineering (1:28:58) - US-Iran Tensions and Military Strategy (2:00:28) - Maga Brain Rot and Political Shifts (2:07:10) - The Role of Media and Public Perception (2:25:11) - The Future of American Democracy (2:27:12) - The Impact of Global Politics on American Society (2:36:07) - The Role of Technology in Shaping the Future (2:36:23) Watch more independent videos at http://www.brighteon.com/channel/hrreport  ▶️ Support our mission by shopping at the Health Ranger Store - https://www.healthrangerstore.com ▶️ Check out exclusive deals and special offers at https://rangerdeals.com ▶️ Sign up for our newsletter to stay informed: https://www.naturalnews.com/Readerregistration.html Watch more exclusive videos here:

Abdominal organ procurement is a high-stakes operation that blends anatomy, speed, and coordinated teamwork. In this Behind the Knife episode, the UNMC transplant team walks through the practical “how-to” of deceased donor abdominal recovery—covering OR roles and logistics, key anatomic maneuvers, cannulation/flush troubleshooting, and the workflow differences that matter most between donation after brain death (DBD) and donation after circulatory death (DCD).HostsMadeline Cloonan, MD PhD – General Surgery Resident, University of Nebraska Medical Center (@maddie_cloonan) Evelyn Waugh, MD – Transplant Surgery Fellow, University of Nebraska Medical Center Jacqueline Dauch, MD – Abdominal Transplant Surgeon, University of Nebraska Medical Center Alex Maskin, MD – Kidney & Pancreas Transplant Surgeon, University of Nebraska Medical CenterLearning Objectives Compare DBD vs DCD donor workflow and define total vs functional warm ischemia.  Identify key OR roles and the ethical/legal separation of death declaration from procurement teams.  Outline the core steps of abdominal procurement, including exposure, cannulation, cross-clamp, and organ removal sequence.  Apply a practical troubleshooting approach when flush flow is inadequate References  Englesbe MJ, Mulholland MW. Operative Techniques in Transplantation Surgery. Philadelphia, PA: Wolters Kluwer; 2018. Tullius SG, Rabb H. Improving the supply and quality of deceased-donor organs for transplantation. N Engl J Med. 2018;378(20):1924–1933. doi:10.1056/NEJMra1708700. https://pubmed.ncbi.nlm.nih.gov/29768153/ Croome KP, Barbas AS, Whitson B, et al. American Society of Transplant Surgeons recommendations on best practices in donation after circulatory death organ procurement. Am J Transplant. 2023;23(2):171–179. doi:10.1016/j.ajt.2022.10.009. https://pubmed.ncbi.nlm.nih.gov/36695685/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Guest: Tyler Anbinder. Highlighting Phelan and Collender's billiard empire, Anbinder concludes by emphasizing the surprising upward mobility and resilience of Famine immigrants in American society

On Tuesday's Mark Levin Show, WMAL's Larry O'Connor fills in for Mark. Why do the Democrats not want to vote on SAVE act? This is a straightforward and uncontroversial bill, as it simply requires proof of U.S. citizenship to register to vote and presentation of photo ID at the polling place on election day. 83% of Americans favor photo ID but Democrats complain that it's racist and for labeling it Jim Crow 2.0. It's not just Democrats, Republican Senate Majority Leader John Thune let this act  sit idle for 300 days and then he downplays it and refuses to force a filibuster fight or making it a top priority. This is weak leadership on a fundamental issue of election integrity. Also, there is progress in resisting the harmful transgender cult pushed by medical professionals, educators, and elites, who pressure parents into allowing minors to undergo irreversible interventions like pharmaceutical hormone treatments and surgeries. There are two recent stories that provide encouraging news: a NY jury awarded $2 million to a young female detransitioner who sued her doctor and psychologist for malpractice after regretting a double mastectomy performed on her as a teenager. Additionally, the American Society of Plastic Surgeons has become the first major U.S. medical association to recommend against gender transition surgeries for youths, advising delays until at least age 19 due to insufficient evidence of benefits outweighing risks. We should celebrate these as victories for common sense, sanity, rational thinking, and child protection. Later, three questions the Democrat party Presidential nominees need to answer: will you reverse President Trump's border polices? Will you tear down the new White House ballroom? Can a man get pregnant? Answering these appropriately to satisfy the current Democratic Party base would secure the nomination but alienate most normal voters in the general election, making a general election win impossible. Learn more about your ad choices. Visit podcastchoices.com/adchoices